α1-antitrypsin with improved properties

Conjugating AAT to an amino acid carrier with Ala, Pro, and Ser residues addresses the limitations of existing therapies by enhancing plasma half-life and stability, providing a safer and more effective treatment for AAT-deficiency diseases.

WO2026234263A1PCT designated stage Publication Date: 2026-11-12GRIFOLS WORLDWIDE OPERATIONS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063481
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-12-19
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current AAT therapies, such as PEG conjugation and FcRn-binding moieties, face challenges like heterogeneous product formation, inefficient manufacturing, and potential modification of amino acid side chains, leading to reduced efficacy and increased complexity, while Fc portion misfolding results in insoluble precipitates.

Method used

Conjugating AAT to an inert amino acid carrier comprising Ala, Pro, and Ser residues, forming a biologically active construct that enhances plasma half-life and maintains elastase activity, stability, and safety.

Benefits of technology

The AAT-based construct achieves prolonged activity and stability, reducing the need for frequent administrations and improving the management of AAT-deficiency related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026063481_12112026_PF_FP_ABST
    Figure EP2026063481_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The invention provides a biologically active construct of formula (I) wherein: (a) the portion P1 represents an amino acid sequence corresponding to an α1-antitrypsin (AAT) glycoprotein; (b) the portion P2 represents an amino acid sequence: having a length from 100 to 3000 amino acid residues, and comprising amino acid repetitive units, wherein (i) the repetitive units are the same or different, and (ii) each one of the repetitive units comprises at least one Ala, at least one Ser, and at least one Pro residue, in any order; and (c) X represents a linker, a peptide bond or a non-peptide bond. The invention also provides nucleic acid encoding this construct of formula (I), vectors, cells and pharmaceutical compositions comprising thereof, as well as therapeutic uses. Advantageously, the construct of the invention is highly stable, efficient and safe. P1-X-P2 (I)
Need to check novelty before this filing date? Find Prior Art

Description

[0001] a1 -ANTITRYPSIN WITH IMPROVED PROPERTIES

[0002] Field of the Invention

[0003] The invention relates to the field of pharmaceutical products, in particular to a1 -antitrypsin. Specifically, the present invention refers to an a1 -antitrypsin conjugated to an amino acid portion having particular features in amino acid composition and length, to compositions comprising thereof and uses in the field of medicine, among others.

[0004] Background of the Invention

[0005] a1 -antitrypsin (hereinafter also referred as “AAT”, also so-called a1 -protease inhibitor (cd PI), “A1AT” or SERPINA1) is a glycoprotein consisting of 394 amino acids and having a molecular weight of about 52 kD. Human AAT is expressed as a 418 amino acid precursor from which a 24 amino acid precursor is clipped to yield the 394 amino acid final product. AAT is synthesized primarily in the liver, but expression has also been demonstrated in neutrophils, monocytes and macrophages.

[0006] AAT is a natural inhibitor of proteases released by activated neutrophils. Its function is to inhibit the activity of certain enzymes, such as elastases, that can damage the lungs.

[0007] When there is a hereditary deficiency of AAT, there is an imbalance between AAT and elastases. Reduced levels of AAT, as in the case of genetic AAT deficiency (AATD), was first identified in 1963 to be the outcome of a variety of mutations in a single gene encoding the human glycoprotein, AAT. The condition is associated most commonly with pulmonary emphysema (due to the unopposed and destructive action of neutrophil proteases in the lungs), as well as with cirrhosis, systemic vasculitis (particularly anti-neutrophil cytoplasmic antibody [ANCA] positive) and neutrophilic panniculitis, among others.

[0008] For the prevention and / or treatment of these AAT deficiency-related diseases, AAT augmentation therapy has been developed. Currently, patients with AAT-deficiency-associated diseases are treated with a high dose of plasma-derived (pd)AAT (60mg / kg / week; Prolastin® from Grifols, Aralast® from Takeda and Zemaira® from CSL) by intravenous infusion.

[0009] In spite of the therapeutic efforts made in this field, the need for weekly travel to a physician / hospital or requirement for nurse visits for intravenous AAT therapy can have a negative effect on patient freedom and quality of life, affecting their ability to fulfill family and work-related tasks, among others.

[0010] It is well-known to those skilled in the art that there are several approaches to improve the profile of a therapeutic protein. Nowadays, however, there is not a clear pointer about how to improve AAT’s profile.In this respect, some prior art has already disclosed the conjugation of AAT to organic inert carriers, such as PEG (cf. Cantin M. A. et al., “Polyethylene glycol conjugation at Cys232 prolongs the half-life of alphal proteinase inhibitor”, 2002, Am J Respir Cell Mol Biol, 27(6):659-665). Typically, the polyethylene glycol (PEG) moiety couples via an aldehyde or N-hydroxysuccinimide (NHS) group on the PEG reacting with an amine group (e.g. lysine side chain or the N-terminus). However, the conjugation step can result in the formation of heterogeneous product mixtures that need to be separated, leading to significant product loss and complexity of manufacturing, and does not result in a completely chemically-uniform product. Also, the pharmacologic function of pharmacologically-active protein may be hampered if amino acid side chains in the vicinity of its binding site become modified by the PEGylation process.

[0011] Some other prior art has reported the role of neonatal Fc receptors (FcRn) in extending the halflife of drugs as well as the suitability of fusing an Fc fragment or albumin to the drug of interest. The binding of the Fc fragment or albumin to FcRn (located in the endosomes), protects the drug from lysosomal degradation. And once the endosome recycles back to the cell surface, the FcRn-complex dissociates in neutral or slightly alkaline conditions (pH 7.0-7.5), releasing the drug back into the bloodstream. Based on this mechanism, attempts are being made with AAT conjugates including such FcRn-binding moieties.

[0012] Unfortunately, it has also been reported in the state of the art that Fc portion does not fold efficiently during recombinant expression and tends to form insoluble precipitates known as inclusion bodies. These inclusion bodies need to be solubilized and functional protein requires to be renatured from the misfolded aggregate, resulting into a time-consuming, inefficient, and expensive process.

[0013] Accordingly, there remains a need for improving the existing therapies in the management of AAT-deficiency related diseases.

[0014] SUMMARY OF THE INVENTION

[0015] The present inventors have found that the AAT profile can be significantly improved by its conjugation to an inert amino acid carrier (portion P2) including amino acid repetitive units comprising Ala, Pro, and Ser residues.

[0016] On one hand, the inventors found that conjugating P2 to AAT, the resulting AAT-based construct showed a significantly longer plasma half-life. As it is shown in Fig. 4, the AAT-based construct of the invention was at a significant higher concentration than the non-conjugated AAT version (hAAT) during a remarkable longer period of time in plasma samples.

[0017] On the other hand, it was also found that the AAT-based construct of the invention retained, and sustained for a longer period of time, AAT’s innate activity (i.e., elastase activity) (see Fig. 2, Table 1 and Fig. 5).The inventors also performed in vitro and in vivo tests with whole blood samples in order to confirm the safety of the AAT-based constructs of the invention. As it is shown in Fig. 3 and 6A-6B, no degradation product, sign of aggregation, or molecular weight modifications were detected. These data are indicative that the constructs of the invention remain stable and, therefore, are safe products, which also represents an advantage with respect to PEG conjugates, for instance. Altogether the data provided herein means a great advancement in the management of AAT-related deficiency diseases, providing a highly stable, efficient and safe AAT product.

[0018] As explained above, until the present invention, the prior art was exploring divergent strategies addressing the problem of how to improve the profile of AAT.

[0019] Unexpectedly, the inventors have found that conjugating AAT to an inert amino acid-based carrier, i.e. portion P2 as defined below, the resulting AAT-based construct shows significant activity which is additionally prolonged in time, stability and safety, overcoming the limitations shown by one of the most commonly carriers used in the state of the art, PEG.

[0020] Therefore, the product provided by the present invention is a robust candidate to improve the life quality of patients suffering from AAT-deficiency related diseases because, in view of its profile, less administrations, due to such advantageous properties, may be required.

[0021] Thus, in a first aspect the present invention provides a biologically active construct of formula (I) or a pharmaceutically salt thereof:

[0022] P1-X-P2 (I)

[0023] wherein:

[0024] (a) P1 represents a first amino acid portion comprising an amino acid sequence corresponding to an a1 -antitrypsin (AAT) molecule; (b) P2 represents a second amino acid portion comprising an amino acid sequence: (a) having a length from 100 to 3000 amino acid residues, and (b) comprising a plurality of amino acid repetitive units, wherein: (i) the repetitive units are the same or different, and (ii) each one of the repetitive units comprises at least one Ala, at least one Ser, and at least one Pro residue, in any order; and (c) X represents a linker, a peptide bond or a nonpeptide bond.

[0025] In a second aspect the present invention provides a nucleic acid molecule encoding the biologically active construct as defined in the first aspect of the invention.

[0026] In a third aspect the present invention provides a vector comprising the nucleic acid molecule as defined in the second aspect of the invention.

[0027] In a fourth aspect the present invention provides a cell comprising the nucleic acid as defined in the second aspect of the invention or the vector as defined in the third aspect of the invention.In a fifth aspect the present invention provides a method for the preparation of the biologically active construct according to the first aspect of the invention which comprises the steps of (a.1) culturing the cell according to the fourth aspect of the invention, and (a.2) isolating said biologically active construct from the culture; or, alternatively, when X is a non-peptide bond or a non-peptide linker, the process comprises conjugating P1 and P2 portions.

[0028] In a sixth aspect the present invention provides a pharmaceutical composition comprising the biologically active construct according to the first aspect of the invention or the vector as defined in the third aspect of the invention, together with one or more pharmaceutically acceptable excipients or carriers.

[0029] Since one of the main therapeutic applications of AAT is focused on lung manifestations of AATD due to insufficient inhibition of neutrophil elastase, including COPD and emphysema, the present inventors analyzed the distribution of the constructs of the invention in lungs. Fig.s 7A and 7B display BALF samples containing AAT_P2_600 and AAT_P2_ (2x200). As it can be derived from the collected data, both constructs were confirmed to be present in all samples analyzed at 10 days after administration. These results confirm that the constructs of the invention are capable of efficiently reaching the pulmonary area after being administered. This is a further indicium of the suitability of the construct of the invention in the management of AAT-deficiency diseases. Thus, in a seventh aspect the present invention provides a biologically active construct as defined in the first aspect of the invention, the vector as defined in the third aspect of the invention or the pharmaceutical composition as defined in the sixth aspect of the invention for use as a medicament.

[0030] In an eighth aspect, the present invention provides a biologically active construct as defined in the first aspect of the invention or the vector as defined in the third aspect of the invention or the pharmaceutical composition as defined in the sixth aspect of the invention for use in the treatment or prevention of a a1-antitrypsin-defficient disease. This aspect can alternatively be formulated as the use of a biologically active construct as defined in the first aspect of the invention or the vector as defined in the third aspect of the invention or the pharmaceutical composition as defined in the sixth aspect of the invention for the manufacture of a medicament for the treatment or prevention of a a1 -antitrypsin-deficient disease. This aspect can alternatively be formulated as a method for the treatment or prevention of a a1 -antitrypsin-deficient disease, the method comprising administering a therapeutically or prophylactically effective amount of a biologically active construct as defined in the first aspect of the invention or the vector as defined in the third aspect of the invention or the pharmaceutical composition as defined in the sixth aspect of the invention.

[0031] Findings from different experimental models reported in the prior art have provided clear evidence that AAT provides broad antimicrobial, anti-inflammatory and immunoregulatory activities (cf. Janciauskiene S. et al., Acute Phase Proteins, Chapter I, “Immunoregulatory Properties of AcutePhase Proteins - Specific Focus on a1 -Antitrypsin”, 2013, http: / / dx.doi.org / 10.5772 / 56393; Bergin D. A. et al., “Alpha-1 Antitrypsin: A Potent Anti-Inflammatory and Potential Novel Therapeutic Agent”, Arch. Immunol. Ther. Exp., 2012, vol. 60, pages 81-97).

[0032] Therefore, in a ninth aspect the present invention provides a biologically active construct as defined in the first aspect of the invention or the vector as defined in the third aspect of the invention or the pharmaceutical composition as defined in the sixth aspect of the invention for use in the treatment or prevention of an infection or inflammatory disease. This aspect can alternatively be formulated as the use of a biologically active construct as defined in the first aspect of the invention or the vector as defined in the third aspect of the invention or the pharmaceutical composition as defined in the sixth aspect of the invention in the manufacture of a medicament for the treatment or prevention of an infection or inflammatory disease. This aspect can alternatively be formulated as a method for the treatment or prevention of infection or inflammatory disease in a subject, the method comprising the administration of a therapeutically effective amount of the biologically active construct as defined in the first aspect of the invention or the vector as defined in the third aspect of the invention or the pharmaceutical composition as defined in the sixth aspect of the invention, to the subject in need thereof.

[0033] In a tenth aspect the present invention provides a biologically active construct as defined in the first aspect of the invention or the vector as defined in the third aspect of the invention or the pharmaceutical composition as defined in the sixth aspect of the invention for use as immunomodulatory agent. This aspect can alternatively be formulated as the use of a biologically active construct as defined in the first aspect of the invention or the vector as defined in the third aspect of the invention or the pharmaceutical composition as defined in the sixth aspect of the invention in the manufacture of a medicament for immunomodulating a disease. This aspect can alternatively be formulated as a method for immunomodulating a disease in a subject, the method comprising administering a therapeutically effective amount of a biologically active construct as defined in the first aspect of the invention or the vector as defined in the third aspect of the invention or the pharmaceutical composition as defined in the sixth aspect of the invention to the subject in need thereof.

[0034] In a last aspect, the present invention provides a kit comprising the biologically active construct as defined in the first aspect of the invention, the nucleic acid as defined in the second aspect of the invention, the vector as defined in the third aspect of the invention, the cell as defined in the fourth aspect of the invention, or the pharmaceutical composition as defined in the sixth aspect of the invention, together with auxiliary means and instructions for the preparation of the construct; or, alternatively, P1 and P2 amino acidic portions in separate compartments together with auxiliary means and instructions for preparing the construct.BRIEF DESCRIPTION OF DRAWINGS

[0035] Fig. 1. ESI / MS spectra of (a) AAT_P2_200 [wherein portion P2 is N-terminally conjugated and consists of SEQ ID NO: 23], (b) AAT_P2_400 [wherein portion P2 is N-terminally conjugated and consists of SEQ ID NO: 24], (c) AAT_P2_600 [wherein P2 is N-terminally conjugated and consists of SEQ ID NO: 25], and (d) AAT_ P2_ (2x200) [wherein P2 is internally conjugated and consists of SEQ ID NO: 26], “c.m” means “calculated mass”.

[0036] Fig. 2. Biological activity at physiological conditions in human whole blood. Each one construct of the invention differing in the size of portion P2 (AAT_P_200 (square), AAT_P2_400 (triangle), AAT_P2_600 (diamond), and AAT_P2_(2x200) (hexagon)), or PBS (cross) as a control, was conducted at 37°C in human whole blood (hWB). The y-axis represents the anti-elastase activity (A. A. expressed in mg / mL) of samples collected at each time point (D(days); day 0, day 1 and day 3) (x-axis). Values are mean ± standard error of the mean (SEM).

[0037] The relative error (RE, %) from baseline activity (activity / activity (t=0) x 100) was also calculated and shown in Table 1.

[0038] Fig. 3. Product stability at physiological conditions in human whole blood. Western blot images showing AAT_P2_200, AAT_P2_400, AAT_P2_600 or AAT_P2_ (2x200) at baseline (day 0) and day 7. The constructs appear with apparent molecular sizes of 120 KDa for AAT_P2_200, 240 KDa for AAT_P2_400 and AAT_P2_(2x200), and >250KDa for AAT_P2_600.

[0039] Fig. 4. In vivo pharmacokinetics analysis. Plasma samples from the animals were assayed for hAAT, AAT_P2_600 and AAT_P2_(2x200) levels using sandwich ELISA. Plasma concentration in human AAT equivalents (P.C [mg / mL], y-axis) of hAAT (cross), AAT_P2_600 (square) and AAT_P2_ (2x200) (triangle) was plotted against Time on scheduled time point (H. hours; x-axis). Data are mean ± standard error of the mean (SEM) (n=6 animals per group).

[0040] Fig. 5. In vivo pharmacokinetics analysis. The anti-elastase activity of plasma samples from animals administered with hAAT (circle), AAT_P2_600 (square) and AAT_P2_(2x200) (triangle) were determined. Anti-elastase activity (A.A) was represented on the y-axis as the relative change fold from baseline (x-fold, “x-f”) vs. time in hours (h, y-axis). Results are presented as the relative change fold and are shown as mean ± SEM (n=6 animals per group).

[0041] Fig. 6. In vivo stability test. Western blot images display AAT_P2_600 (Fig. 6A) or AAT_ P2_(2x200) (Fig. 6B) levels of plasma samples from representative animals (1, 2 and 3), at baseline (5min) and day 10 (1 Od). The proteins appear with apparent molecular sizes of over 250KDa for AAT_P2_600 and 240KDa for AAT_P2_(2x200).

[0042] Fig. 7. Preliminary lung distribution study. Qualitative detection of the either AAT_P2_600 (Fig.

[0043] 7A) or AAT_P2_(2x200) (Fig. 7B) in BALF from animals administered with AAT_P2_600 or AAT_P2_(2x200) (n=6 animals per group). Both proteins were detected by Western Blot at day10. Proteins present a molecular size of 190 kDa for AAT_P2_600 and 150 kDa for AAT_P2_ (2x200).

[0044] Fig. 8. Constructs exemplified in the section of examples.

[0045] DETAILED DESCRIPTION OF THE INVENTION

[0046] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention.

[0047] Throughout the present specification and the accompanying clauses, the words "comprise" and variations such as "comprises", "comprising" are to be interpreted inclusively. That is, these words are intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows. The word “comprise” also includes the term “consists of”.

[0048] For the purposes of the present invention, any ranges given include both the lower and the upper end-points of the range.

[0049] Definitions

[0050] As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.

[0051] The term “amino acid” refers to a molecule containing both an amino group and a carboxyl group. Amino acids are found in nature as isolated molecules and as part of polypeptides, then chemically linked via condensation and also called residues. Unless otherwise explicitly stated, the amino acid can have L- or D-configuration. Amino acids can be classified by the side chain group. There are basically four different classes of amino acids determined by different side chains: (1) non-polar, (2) polar and neutral (uncharged polar), (3) acidic and polar (hereinafter also referred as “acid” or “acidic” amino acids), (4) basic and polar (hereinafter also referred as “basic” amino acids).

[0052] Suitable amino acids include, without limitation, a-amino acids such as L-isomers of the 20 common naturally occurring a-amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; natural beta-amino acids (e.g., betaalanine); and unnatural amino acids. The term “natural L-amino acid” means the L optical isomer forms of glycine (G), proline (P), alanine (A), valine (V), leucine (L), isoleucine (I), methionine (M),cysteine (C), phenylalanine (F), tyrosine (Y), tryptophan (W), histidine (H), lysine (K), arginine (R), glutamine (Q), asparagine (N), glutamic acid (E), aspartic acid (D), serine (S), and threonine (T). Further amino acids suitable in the context of the invention include unnatural (also so-called “modified amino acids”). There are many known unnatural amino acids any of which may be included in the portions of the present invention. Some examples of unnatural amino acids are provided in Table A below, and include 4-hydroxyproline, desmosine, gamma-aminobutyric acid, beta-cyanoalanine, norvaline, 4-(E)-butenyl-4(R)-methyl-N-methyl-L-threonine, N-methyl-L-leucine, 1 -amino-cyclopropanecarboxylic acid, 1-amino-2-phenyl-cyclopropanecarboxylicacid, 1-amino-cyclobutanecarboxylic acid, 4-amino-cyclopentenecarboxylic acid, 3-amino-cyclohexanecarboxylic acid, 4-piperidylacetic acid, 4-amino-1-methylpyrrole-2-carboxylic acid, 2,4-diaminobutyric acid, 2,3-diaminopropionic acid, 2,4-diaminobutyric acid, 2-aminoheptanedioic acid, 4-(aminomethyl)benzoic acid, 4-aminobenzoic acid, ortho-, meta- and para-substituted phenylalanines (e.g., substituted with — C(=O)C6H5; — CF3; — CN; -halo; — NO2; — CH3), disubstituted phenylalanines, substituted tyrosines (e.g., further substituted with — C(=O)C6H5; — CF3; — CN; -halo; — NO2; — CH3), and statine. Additionally, the amino acids suitable for use in the present invention may be derivatized to include amino acid residues that are hydroxylated, phosphorylated, sulfonated, acylated, lipidated, and glycosylated, to name a few.Table A: illustrative examples of unnatural amino acids

[0053] A b b ro v ru1o n f 'Indsf 'nc<Arn'rn irrf

[0054] Aad 2-Amhoadipic add

[0055] bAad 3-Arrmoadipic acid

[0056] bAla beta-Alamne. beta-Aminoproprionfc add

[0057] Abu 2-AminobutyiicacW

[0058] 4Abu 4-Aminobutync acid, pipendimc acid

[0059] Acp 6-Aminocaproic add

[0060] Ahe 2-Aminoheptanoic add

[0061] Aib 2-Ammoisobutyric acid

[0062] bAib 3«Aniinoisobu^rfcacid

[0063] Apm 2-Aminopfcnefc acid

[0064] Dbu 2,4-Diaminobutyrfc acid

[0065] Des Desmosine

[0066] Dpm 2.2 -Diaminopimelic acid

[0067] Opr 2,3-Oiamiroproprionfc add

[0068] EtGly N-Ethy^lycine

[0069] EtAsn N-Etfjylasparagine

[0070] Hyl Hydroxylysine

[0071] aHyl allo-Hydroxylysine

[0072] 3Hyp 3-Hydroxyprohne

[0073] 4Hyp 4-Hydroxyprohne

[0074] Icfe Isodesmosine

[0075] al!e allo-lsoleucine

[0076] MeGly N-Methylglyctne. sarcosine

[0077] Welle N-MeBylisoleucine

[0078] MeLys 6-N-Methyllysme

[0079] MeVal N-Methylvaline

[0080] Nva Norvaline

[0081] Nle Norleucme

[0082] Om Ornithine

[0083]

[0084] Amino acids used in the production of the construct of the present invention may be prepared by organic synthesis, or obtained by other routes, such as, for example, degradation of or isolation from a natural source.

[0085] The terms “polypeptide”, “peptide”, and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompassan amino acid polymer that has been modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.

[0086] In the context of the present invention, the term “pharmaceutically salt thereof” when referring to the construct as provided herein, encompasses those salts which are, within the scope of sound medical judgment, suitable for use in humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. Examples of pharmaceutically acceptable, non-toxic acid addition salts include acid addition salts and base addition salts. Illustrative non-limitative examples are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, trifluoroacetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other illustrative non-limitative pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2 naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal ion, alkaline earth metal ion, and ammonium. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further illustrative non-limitative pharmaceutically acceptable salts include, when appropriate, non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. As used herein, the term "portion" relates to any region / part of an amino acid sequence that is capable of autonomously adopting a specific structure and / or function. In the context of the present invention, accordingly, a "portion" may represent a functional portion or a structural portion. As described herein, the constructs of the present invention comprise at least one portion / part having biological activity (AAT, “portion P1”) and at least one stabilizing portion (“portion P2”). Yet, the constructs of the invention may also comprise more than two portions and may comprise e.g. an additional linker structure between the herein defined two portions, another portion / part like, e.g. a protease sensitive cleavage site, an affinity tag such as the His6-tag or the Strep-tag, a signal peptide, retention peptide, a targeting peptide like a membrane translocation peptide or additional effector portions.In the context of the invention, the term “inert”, when referred to portion P2, means that this portion is biologically inert in one or more of proteolysis in blood plasma, immunogenicity, isoelectric point / electrostatic behaviour, binding to cell surface receptors as well as internalization, but still biodegradable under certain conditions (e.g., in the presence of harsh proteases) or in certain cell compartments (e.g., in lysosomes).

[0087] The terms “polynucleotides”, “nucleic acids”, and “oligonucleotides” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, single-stranded DNA, double-stranded DNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.

[0088] “Recombinant” as applied to a polynucleotide means that the polynucleotide is the product of various combinations of in vitro cloning, restriction and / or ligation steps, polymerase chain reaction (PCR), and other procedures that result in a construct that can potentially be expressed in a host cell.

[0089] “Conjugated”, “linked,” “fused,” and “fusion” refer to the joining together of two or more chemical or biochemical elements or components, by whatever means including chemical conjugation or recombinant means (for example peptide portions P1 and P2). For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and in reading phase or in-frame. An “in-frame fusion” refers to the joining of two or more open reading frames (ORFs) to form a continuous longer ORF, in a manner that maintains the correct reading frame of the original ORFs. Thus, the resulting recombinant fusion protein is a single protein containing two or more segments that correspond to polypeptides encoded by the original ORFs (which segments are not normally so joined in nature).

[0090] As used herein, “treat”, “treating,” “treatment” or “ameliorating” are used interchangeably and mean administering a drug or a biologic to achieve a therapeutic effect or benefit, to cure or reduce the severity of an existing disease, disorder or condition, or to achieve a prophylactic benefit, prevent or reduce the likelihood of onset or severity of the occurrence of a disease, disorder or condition.A “therapeutic effect” or “therapeutic benefit,” as used herein, refers to a physiologic effect, including but not limited to the cure, mitigation, amelioration, or prevention of disease in humans or other animals, or to otherwise enhance physical or mental well-being of humans or animals, caused by a polypeptide of the invention other than the ability to induce the production of an antibody against an antigenic epitope possessed by the biologically active protein. For “prophylactic benefit”, the compositions may be administered to a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.

[0091] A "therapeutically effective amount" and “therapeutically effective dose” are used interchangeably and refer to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of AAT may vary according to factors such as the disease state, age, sex, and weight of the individual subject, and the ability of the AAT to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of AAT are outweighed by the therapeutically beneficial effects.

[0092] A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as, for example, preventing or inhibiting emphysema associated with congenital deficiency of AAT. A prophylactically effective amount can be determined as described above for the therapeutically effective amount.

[0093] The term “therapeutically effective dose regimen”, as used herein, refers to a schedule for consecutively administered multiple doses (i.e., at least two or more) of the construct of the first aspect of the invention, the nucleic acid of the second aspect of the invention, the vector of the third aspect of the invention, the cell of the fourth aspect of the invention or the pharmaceutical composition of the sixth aspect of the invention, wherein the doses are given in therapeutically effective amounts to result in sustained beneficial effect on any symptom, aspect, measured parameter or characteristics of a disease state or condition.

[0094] In a first aspect the present invention provides a biologically active construct of formula (I).

[0095] P1 portion: AAT or functional fragment thereof

[0096] “Alpha-1 antitrypsin” or “AAT” means an acute phase blood glycoprotein protease inhibitor belonging to the serpin superfamily and species and sequence variants thereof that includes, but is not limited to, the 394 amino acid mature form of approximately 52 kDa, as well as glycoforms. Alpha 1-antitrypsin is the main protein of the alpha-globulin 1 region of human plasma.

[0097] AAT is encoded by a 12.2 kb, 7-exon gene at q31-31.2 on chromosome 14. AAT functions by presenting its reactive centre methionine residue on an exposed loop of the molecule such that it forms an ideal substrate and / or inhibitor for the enzyme neutrophil elastase.AAT is a complex N-glycosylated protein, and its glycosylation is essential for correct folding, secretion, stability, circulatory half-life, and biological activity.

[0098] Human AAT contains three conserved N-linked glycosylation sites whose exact location depends on the form. For instance, in the precursor form (Uniprot P01009) the three N-glycosylation sites are located at: Asn70, Asn107, and Asn271, whereas in the mature form (Uniprot Pro0000032377), they may be located at Asn46, Asn83 and Asn247 positions or, alternatively, at Asn46, Asn83 and Asn246 (See for instance, Kolarich D. et al., “Comprehensive glyco-proteomic analysis of human alphal -antitrypsin and its charge isoforms”, 2006, Proteomics, 6(11):3369-3380). Each site is occupied by complex-type N-glycans, exhibiting extensive microheterogeneity in terms of branching (antenarity), fucosylation, and sialylation. Importantly, the glycosylation profile of AAT is site-specific: Asn70 (or its equivalent Asn46 in the mature form) predominantly carries bi-antennary glycans, Asn107 (or its equivalent Asn83 in the mature form) shows the highest heterogeneity, including bi-, tri-, and occasional tetra-antennary structures, and Asn271 (or its equivalent, Asn246 / Asn247 in the mature form) is largely restricted to bi-antennary glycans. This heterogeneity directly affects the net charge of the molecule, giving rise to multiple glyco-isoforms (also so-called glycoforms).

[0099] Naturally occurring AAT circulates as a mixture of glycoforms designated MO to M8. These isoforms are at least partly due to variable sialylation and branching of N-glycans. The state of the art provides details about how to characterize these glycoforms in any AAT sample (see for instance Kolarich D. et al, supra, as well as Arora V. et al., “Comparison of the liquid and lyophilized formulations of Prolastin®-C for Alphal -Antitrypsin deficiency: Biochemical characteristics, pharmacokinetics, safety and neoantigenicity in rabbits”, Biologicals, 62, 77-84, 2019, whose content is incorporated herein by reference). These are well-known and routine methods and form part of the general knowledge of the skilled person in the art.

[0100] An illustrative embodiment to characterize the AAT glycoform composition would include performing an isoelectric focusing (IEF) band alignment. This step may include performing a gel electrophoresis in the presence of ampholytes (e.g., pH 3-7) with subsequent gel staining (e.g., Coomassie). Subsequently each M-band may be identified by co-migration to reference standards. An unknown AAT species is classified as Mx if it co-migrates with the corresponding Mx reference band under the defined IEF conditions (e.g., reference A1PI preparations displaying known M-band patterns).

[0101] A second-tier confirmatory step may be used, excising the IEF band and digesting with trypsin or chymotrypsin (the latter for the unambiguous detection of the N-terminus in M7 / M8). If lEF-band shows N-terminal truncation (major start at residue 30), the glycoform is candidate to be M7 or M8 glycoform (the definitive confirmation will be provided by the glycan signature (see below)). If no truncation is detected, the glycoform will be confirmed to be M2 / M4 / M6 classify by glycan signature or by IEF co-migration (other M-bands).After completing the IEF characterization, the analysis of the site-specific glycan signature (N70 / N107 / N271 or N46 / N83 / N247) is performed. This step translates IEF band identity into structural glycan criteria using the site-specific approaches described for the mapped isoforms: (a) Identify site-specific glycopeptides and determine antennarity:

[0102] a.1. performance of LC-ESI-MS and / or LC-ESI-MS / MS of proteolytic digests to determine glycan occupancy / structures on the glycopeptides corresponding to N70 (N46) , N107(N83), and N271 (N246 or N247), as it is disclosed, for instance by Kolarich D. et al., supra, (section 2.3.); or, alternatively,

[0103] a.2. analysis of the AAT sample by reversed-phase high performance liquid chromatography-mass selective single quadrupole detector (LC-MSD), as disclosed by Arora V. et al., supra, (section 2.1.1);

[0104] (b) Interpretation rules (structural classifiers):

[0105] - Classify as M6 if N70 (N46), N107(N83), N271 (N246 or N247) are each predominantly bi-antennary.

[0106] - Classify as M4 if N107 (N83) is predominantly tri-antennary, while N271 (N246 or N247) remains bi-antennary and N70 (N46) is predominantly bi-antennary.

[0107] - Classify as M2 if N 107 (N83) includes tri- and tetra-antennary glycans (tetra-antennary at N107 (N83) described as a main driver for M2 migration), while N271 (N247) remains bi- antennary.

[0108] - Classify as M7 if the band is N-terminally truncated and its glycan pattern is M4-like (notably tri-antennary at N 107 (N83)).

[0109] - Classify as M8 if the band is N-terminally truncated and its glycan pattern is M6-like (notably bi-antennary at N 107 (N83)).

[0110] - Classify as M3 if N107 (N83) is exclusively or predominantly tri-antennary, and neither tetra-antennary glycans at N107 (N83) nor N-terminal truncation are detected, while N70 (N46) and N271 (N246 or N247) remain predominantly bi-antennary. In this context, M3 represents an intermediate glycosylation state characterized by tri-antennary branching at N 107 (N83) without progression to tetra-antennary structures. - Classify as M1 if the glycosylation pattern deviates from M3 and M2 by the presence of rare and non-dominant combinations of higher-order branching, including but not limited to tri-antennary glycans at N70 (N46) and / or a mixed population of tri- and tetra-antennary glycans at N 107 (N83), without N-terminal truncation and without a single glycan population being sufficiently predominant to qualify as M2 or M3.

[0111] - Classify as M0 if the AAT protein lacks N-glycosylation at one or more of the canonical glycosylation sites N70 (N46), N107 (N83) and N271 (N246 or N247), or if the overallglycosylation level is below that characteristic of physiologically occurring plasma AAT. MO thus refers to non- or poorly glycosylated AAT species and does not correspond to the physiological M-type glycoforms observed in human plasma.

[0112] (c) Optional linkage / epitope confirmation (if needed): Where higher granularity is required (e.g., to strengthen a structural definition), perform exoglycosidase digests to support: a2,6 Neu5Ac on di-antennary structures; the presence of one a2,3 Neu5Ac on tri-antennary structures; fucose consistent with sLeX determinants on branched glycans; and marginal core a1,6 fucosylation on di-antennary structures.

[0113] In addition to, or as an alternative to, the above, an intact protein LC-MS (e.g., LC-MSD) profile can be used as an orthogonal check for the presence of major glycoforms, as illustrated for A1 PI products (including deconvoluted masses and band assignments dominated by M6 and M4). In addition to fully glycosylated forms, alpha-1 antitrypsin (AAT) may also exist as partially glycosylated, characterized by incomplete occupancy of one or more of the native N-linked glycosylation sites. Such partially glycosylated AAT species may arise naturally during biosynthesis, under specific physiological or pathological conditions, or as a result of controlled or uncontrolled expression in recombinant systems.

[0114] Accordingly, within the context of the present invention, the term “glycoprotein”, when referring to AAT, encompasses fully glycosylated AAT as well as partially glycosylated AAT molecules defined by a specific degree of N-glycan site occupancy. In one embodiment AAT comprises fully glycosylated AAT (i.e., all three Asn sites are glycosylated). In another embodiment AAT comprises partially glycosylated AAT (i.e., incomplete occupancy of one or more of the native N-linked glycosylation sites). In one embodiment AAT glycoprotein consists of fully glycosylated AAT. In another embodiment AAT glycoprotein consists of a partially glycosylated AAT. In another embodiment, AAT glycoprotein consists of one glycoform selected from MO to M8. In another embodiment AAT comprises a mixture of fully and partially glycosylated AAT glycoforms. In another embodiment AAT comprises a mixture of partially glycosylated AAT glycoforms. In another embodiment, AAT glycoprotein comprises a mixture of two or more glycoforms selected from MO to M8. In another embodiment, AAT glycoprotein comprises a mixture of glycoforms M4 and M6. In another embodiment AAT glycoprotein comprises a mixture of glycoforms M4, M6, M2 and M7. In another embodiment, AAT glycoprotein comprises a mixture of glycoforms M4, M6, M2 and M7, wherein each of glycoforms M4 and M6 is present ata percentage by weight, relative to the total AAT glycoprotein, that is higher than the percentage by weight of each of glycoforms M2 and M7.

[0115] The term "AAT" glycoprotein, as used herein, is intended to be understood in its broadest sense, unless specifically stated otherwise. Thus, the term encompasses any naturally occurring form of AAT (human and homologues thereof), either in the form of precursor or mature form. This term also encompasses any isolated AAT glycoform selected from MO to M8, as well as any mixtureof such glycoforms, whether naturally occurring or artificially produced. The term also encompasses non-naturally occurring variants obtained by analogous substitution of one or more amino acids of AAT. The term also encompasses any AAT polypeptide that is a product of recombinant DNA technology, including AAT that is a product of transgenic technology. For example, the gene coding for AAT can be inserted into a mammalian gene encoding a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland as described in U.S. Patent No. 5,322,775. The term also refers to any AAT protein synthesized chemically by means well known in the art such as, e.g., solid-phase peptide synthesis. The term also refers to AAT prepared from plasma. The term also refers to AAT that is commercially available. For example, Prolastin® (Grifols Therapeutics, Inc., Research Triangle Park, NC), Prolastin®-C (Grifols Therapeutics, Inc., Research Triangle Park, NC) Arora V. et al. “Comparison of the liquid and lyophilized formulations of Prolastin®-C for Alphai-Antitrypsin deficiency: Biochemical characteristics, pharmacokinetics, safety and neoantigenicity in rabbits”, 2019, Biologicals, 62:77-84), Prolastin®-C Liquid (Grifols Therapeutics, Inc., Research Triangle Park, NC), Aralast™ (Takeda Pharmaceuticals USA, Lexington, MA) and Zemaira ® (CSL Behring, Kankakee, IL) are prepared from pools of human plasma. AAT from human plasma also is commercially available from Sigma-Aldrich Chemical Co. as products A9024, A6150, and 10814 (Sigma-Aldrich Chemical Co., Milwaukee, Wl). AAT also is available from PPL Therapeutics, East Mains, Ormiston, East Lovian, EH35 5NG, Scotland. U.S. Patent No. 6,974,792 describes a method of preparing AAT.

[0116] Homologue sequences to human AAT may be found by standard homology searching techniques, such as NCBI BLAST, or in public databases such as Chemical Abstracts Services Databases (e.g., the CAS Registry), GenBank, among others. These homologue sequences of AAT may share at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% amino acid sequence homology compared with the reference biologically active protein (e.g. human AAT), and retain at least a portion of the therapeutic and / or biological activity of the biologically active protein.

[0117] It will be appreciated that various amino acid deletions, insertions and substitutions can be made in the AAT to create variants without departing from the spirit of the invention with respect to the biological activity or pharmacologic properties of the AAT. Examples of conservative substitutions for amino acids in polypeptide sequences are shown in Table B below.TABLE B

[0118] Exemplary conservative amino acid substitutions

[0119] Original Residue Exemplary Substitutions

[0120] Ala (A) Vai; Leu; lie

[0121] Arg (R) Lys; Gin; Asn

[0122] Asn (N) His; Lys; Arg

[0123] Asp (D) Glu

[0124] Cys (C) Ser

[0125] Gin (Q) Asn

[0126] Glu (E) Asp

[0127] Gly (G) Pro

[0128] His (H) Asn, Lys, Arg

[0129] He (I) Leu; Vai; Met; Ala; Phe: Norleucine

[0130] Leu (L) Norleucine: lie: Vai; Met; Ala: Phe

[0131] Lys (K) Arg; Asn

[0132] Met (M) Leu; Phe; lie

[0133] Phe (F) Leu: Vai: lie; Ala

[0134] Pro (P) Gly

[0135] Ser (S) Thr

[0136] Thr (T) Ser

[0137] Trp (W) Tyr

[0138] Tyr (Y) Trp: Phe: Thr: Ser

[0139] Vai (V) lie; Leu; Met; Phe; Ala; Norleucine

[0140] In embodiments of the first aspect of the invention in which the sequence identity of the AAT is less than 100% compared to a specific sequence disclosed herein, the invention contemplates substitution of any of the other 19 natural L-amino acids for a given amino acid residue of the given AAT, which may be at any position within the sequence of the AAT, including adjacent amino acid residues.

[0141] In addition, variants can include, for instance, polypeptides wherein one or more amino acid residues are added or deleted at the N- or C-terminus of the full-length native amino acid sequence of an AAT that retains some if not all of the biological activity of the native peptide; e.g., the ability to inactivate a protease such as trypsin or elastase. Such AAT variants are known in the art. Illustrative non-limitative examples are provided by US4711848 or US20100048680, whose content is incorporated herein by reference.

[0142] The expression “corresponding to an AAT” when referred to peptide portion P1, means that P1 comprises or consists of an AAT as defined in any of the above or below passages.

[0143] In one embodiment of the first aspect of the invention, P1 comprises or consists of the full-length amino acid sequence of AAT. This embodiment encompasses a portion P1 comprising a full-length human AAT (either as precursor or mature form), a full-length (either as precursor ormature form) homologue to human AAT sequence (including domestic animals), a recombinant or a variant thereof. Illustrative non-limitative examples of AAT sequences useful in the context of the invention are provided as sequences SEQ ID NO: 1 to 14. Any of the AAT sequences suitable in the context of the invention can be constructed by shuffling individual mutations into and between the amino acids of the sequences SEQ I D NO: 1 to 14. The resulting AAT sequences can be evaluated for activity and those that retain at least a portion of the biological activity of the native AAT may be useful for the protein products of this invention.

[0144] In another embodiment of the first aspect of the invention, P1 comprises or consists of a functional fragment of AAT. In the context of the present invention, the term “functional fragment” encompasses any fragment of AAT retaining at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the biologic activity or biological function of the mature AAT. There are several protocols already known and easy-available to those skilled in the art to determine the biological function in the native and fragment thereof. For example, enzyme inhibition assay as the one disclosed in Gaillard Me et al., “Determination of functional activity of alpha 1-protease inhibitor and alpha 2-macroglobulin in human plasma using elastase”, J. Clin. Chem. Clin Biochem., 1987, 25(3): 167-172; or Bournouf T. et al., “Biochemical and biological properties of an alpha 1 -antitrypsin concentrate”, 1987, Vox sang, 52(4):291-297. Alternatively, human leukocyte elastase (HLE) inhibitory capacity can also be determined by Cantin et al., "Polyethylene glycol conjugation at Cys232 prolongs the half-life of alphal proteinase inhibitor", 2002, 27: 659-665. An alternative illustrative test, is also provided in the examples below, based on determining elastase activity.

[0145] In one embodiment of the first aspect of the invention, the functional fragment of AAT retains at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the elastase activity exhibited by the mature (full-length) AAT. The elastase activity can be determined following any routine protocol, such as the one provided below in the section of examples. Functional fragments from sequences SEQ ID NO: 1 to 14 can be routinely identified using any of the well-known techniques and bioinformatic tools.

[0146] In one embodiment of the first aspect of the invention, P1 comprises the mature sequence of an AAT or a functional fragment of the mature sequence. In another embodiment of the first aspect of the invention, P1 consists of the mature sequence of an AAT or a functional fragment of the mature sequence.

[0147] In one embodiment of the first aspect of the invention, P1 comprises an AAT sequence with at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to an amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 14 or any functional fragment thereof. In one embodiment of the first aspect of the invention, P1 comprises an amino acidic sequence with at least 80%, or alternatively with 81%, 82%, 83%, 84%, 85%,86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, of sequence identity with respect to SEQ ID NO: 2 or any functional fragment thereof. In one embodiment of the first aspect of the invention, P1 consists of an amino acidic sequence with at least 80%, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, of sequence identity with respect to SEQ ID NO: 2 or any functional fragment thereof. In another embodiment of the first aspect of the invention, P1 consists of SEQ ID NO: 2 or a functional fragment thereof.

[0148] “Percent (%) sequence identity,” with respect to the polypeptide sequences identified herein, is defined as the percentage of amino acid residues in a query sequence that are identical with the amino acid residues of a second, reference polypeptide sequence or a portion thereof, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Percent identity may be measured over the length of an entire defined polypeptide sequence, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0149] In one embodiment, portion P1 has an amino acid length higher or lower than the amino acid length of portion P2; particularly, portion P1 has an amino acid length corresponding to at least 60% of portion P2 amino acid length. More particularly, portion P1 has an amino acid length within the range defined by the length of portion P2 amino acid ± 40%, particularly within the range defined by the length of portion P2 amino acid ± 30%, particularly within the range defined by the length of portion P2 amino acid ± 20%, particularly within the range defined by the length of portion P2 amino acid ± 10%. In these embodiments the ends are considered within the ranges.Portion P2 including amino acid repetitive units

[0150] In accordance with this invention, the biologically active construct of the invention includes a portion P2 comprising a plurality of amino acid repetitive units including at least one Ala, at least one Pro and at least one Ser, in any order.

[0151] In the context of the present invention the expression “amino acid repetitive unit” and “repetitive unit” are used interchangeably and refer to an amino acid sequence (pattern) which is repeated several times in portion P2.

[0152] In the context of the invention, portion P2 may be a homopolymer in the sense of having a single repetitive unit, a random copolymer as having two or more repetitive units which do not form an identical repeating pattern, or a block copolymer, where at least one of the repeating units forms a block of at least 2 repetitive units, more usually at least 3 repetitive units, frequently 4 or more, generally not more than about 50 repetitive units, frequently not more than about 30 repetitive units. In one embodiment of the first aspect of the invention, the repetitive units comprised in P2 are the same (i.e. , P2 is a homopolymer).

[0153] In another embodiment of the first aspect of the invention, the repetitive units have an amino acid length from 3 to 50 amino acids, particularly an amino acid length of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids.

[0154] In another embodiment of the first aspect of the invention, the plurality of repetitive units are the same, and the repetitive units have an amino acid length from 15 to 25 amino acids, particularly of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids.

[0155] In one embodiment of the first aspect of the invention, portion P2 consists of at least about 100 amino acid residues, at least about 150 amino acid residues, at least about 200 amino acid residues, at least about 250 amino acid residues, at least about 300 amino acid residues, at least about 350 amino acid residues, and at least about 400 amino acid residues. In another embodiment, the amino acid sequence forming P2 consists of maximally about 1000 amino acid residues, preferably of maximally about 900 amino acid residues, more preferably of maximally about 800 amino acid residues, even more preferably of maximally about 700 amino acid residues, particularly preferably of maximally about 650 amino acid residues. It is also envisaged herein that the amino acid sequence forming P2 may consist of maximally about 1200, about 1500 and up to about 3000 amino acid residues. Accordingly, the amino acid sequence forming P2 may consist of about 100 to about 3000 amino acid residues. In particular embodiments said amino acid sequence forming P2 consists of about 100 to 1000 amino acid residues as characterized herein, i.e. comprising alanine, serine and proline as main or unique residues. In another embodiment of the first aspect of the invention, the repetitive units comprised in P2 represent at least about 50%, at least about 65%, at least about 75 %, at least about 80 %, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%,at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the amino acids forming the portion P2.

[0156] In another embodiment of the first aspect of the invention, the total content of Ala is equal or higher than the total content of Pro and Ser residues in portion P2.

[0157] In another embodiment of the first aspect of the invention, the total content of Pro is higher than the total content of Ser residues in portion P2.

[0158] In the context of the present invention, the “total content” of an amino acid (e.g., Ala or Pro) is calculated dividing the number of times that the particular amino acid is incorporated in portion P2 by the total number of amino acids forming portion P2.

[0159] In one embodiment of the first aspect of the invention, proline residues represent preferably about 4 % to about 40 %, whereas the total of alanine and serine residues is from 60 % to 96 % of the total amino acidic composition of P2, provided that the sum does not exceed the 100%.

[0160] In another embodiment of the first aspect of the invention, Pro residues constitute from 4% to 50%, particularly from 10% to 45%, particularly from 15% to 40%, particularly from 20% to 40% of the total number of amino acids forming portion P2.

[0161] In another embodiment of the first aspect of the invention, Ala residues constitute from 4% to 60 %, particularly from 10% to 55%, particularly from 20% to 55% of the total number of amino acids forming portion P2.

[0162] In another embodiment of the first aspect of the invention, Ser residues constitute from 4% to 50%, particularly from 10% to 45%, particularly from 20% to 40% of the total number of amino acids forming portion P2.

[0163] In another embodiment of the first aspect of the invention, the total amino acid composition of P2 comprises about 30-40 % proline residues, about 45-55 % alanine residues and about 10-20 % serine residues of the amino acids constituting P2, provided that the sum does not exceed the 100%; particularly, the total amino acid composition of P2 comprises about 35 % proline residues, about 50 % alanine residues and about 15 % serine residues, provided that the sum does not exceed the 100%.

[0164] In another embodiment of the first aspect of the invention, the total amino acid composition of P2 comprises from about 30-40 % proline residues, about 10-20 % alanine residues and about 45-55 % serine residues, provided that the sum does not exceed the 100%; particularly, the total amino acid composition of P2 comprises about 35 % proline residues, about 15 % alanine residues and about 50 % serine residues, provided that the sum does not exceed the 100%. In another embodiment of the first aspect of the invention, the repetitive units consist of one or more Ala, one or more Ser, and one or more Pro residues, in any order.In another embodiment of the first aspect of the invention, portion P2 includes no more than 6 consecutive amino acid residues are identical, particularly no more than 5 identical consecutive amino acid residues, particularly no more than 4 identical consecutive amino acid residues, particularly no more than 3 identical consecutive amino acid residues.

[0165] In another embodiment, the amino acidic composition of P2 consists of Ala, Ser, and Pro residues and no more than 3, no more than 4, no more than 5, or no more than 6 consecutive amino acid residues are identical.

[0166] In another embodiment of the first aspect of the invention, portion P2 consists of alanine, serine and proline residues; particularly portion P2 consists of alanine, serine and proline residues and the plurality of repetitive units are the same; particularly P2 consists of alanine, serine and proline residues and the plurality of repetitive units are the same and no more than 3, no more than 4, no more than 5, or no more than 6 consecutive amino acid residues are identical.

[0167] In an alternative embodiment of the first aspect of the invention, portion P2 comprises up to 10%, particularly up to 8%, particularly up to 6%, particularly up to 5%, particularly up to 4%, particularly up to 3%, particularly up to 2%, particularly up to 1% of amino acids different from alanine, serine and proline. Said amino acids different from alanine, serine and proline may be selected from the group consisting of Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Vai.

[0168] In an alternative embodiment of the first aspect of the invention, P2 amino acid sequence is as defined in any of the above embodiments, and further includes from 1 to 10, particularly from 1 to 5 amino acids other than Ser, Pro and Ala. In a particular embodiment of the first aspect of the invention, P2 amino acidic sequence is of a length and amino acidic composition in Pro, Ser and Ala as defined in any of the above embodiments, and further includes 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids selected from the group consisting of: Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Vai; particularly from the group consisting of Cys and Lys. In a particular embodiment of the first aspect of the invention, P2 amino acidic sequence has a length from 100 to 1000 amino acid residues, particularly from 200 to 800 amino acid residues, particularly from 350 to 650 amino acid residues, and 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 of said amino acids are selected from the group consisting of: Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Vai. In a particular embodiment of the first aspect of the invention, P2 amino acidic sequence has a length from 100 to 1000 amino acid residues, particularly from 200 to 800 amino acid residues, particularly from 350 to 650 amino acid residues, and 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 of said amino acids are selected from the group consisting of: Cys and Lys.

[0169] In another embodiment of the first aspect of the invention, portion P2 comprises at least two of the amino acid repetitive units separated by one or more amino acids, particularly by 1, 2, 3, 4 or 5 amino acids.In another embodiment of the first aspect of the invention, two of the amino acid repetitive units are separated by one or more amino acids, particularly by 1, 2, 3, 4 or 5 amino acids.

[0170] In another embodiment of the first aspect of the invention, at least two amino acid repetitive units are separated by at least one amino acid other than Ser, Pro or Ala; particularly the at least two amino acid repetitive units are separated by 1, 2, 3, 4, or 5 amino acid residues selected from Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Vai; particularly the at least two amino acid repetitive units are separated by 1 , 2, 3, 4, or 5 amino acid residues, the same of different, selected from Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Vai; particularly the at least two amino acid repetitive units are separated by 1, 2, 3, 4, or 5 amino acid residues, the same or different, selected from Cys and Lys; particularly the at least two amino acid repetitive units are separated by one amino acid residue selected from Cys and Lys.

[0171] In another embodiment of the first aspect of the invention, portion P2 comprises two of the amino acid repetitive units separated by 2, 3, 4 or 5 amino acids, wherein at least one of these amino acids is other than Ser, Pro or Ala.

[0172] In one embodiment of the first aspect of the invention, the at least one amino acid(s) other than Ser, Pro and Ala is involved in the conjugation to P1.

[0173] In another embodiment of the first aspect of the invention, the amino acid repetitive unit is selected from ASPAAPAPASPAAPAPSAPA (SEQ ID NO: 15), AAPASPAPAAPSAPAPAAPS (SEQ ID NO: 16), SAPSSPSPSAPSSPSPASPS (SEQ ID NO: 17), APSSPSPSAPSSPSPASPSS (SEQ ID NO. 18), SAPSSPSPSAPSSPSPASPS (SEQ ID NO: 19), SSPSAPSPSSPASPSPSSPA (SEQ ID NO: 20), AASPAAPSAPPAAASPAAPSAPPA (SEQ ID NO: 21) and ASAAAPAAASAAASAPSAAA (SEQ ID NO: 22). SEQ ID NO: 19 corresponds to a circularly permuted form of SEQ ID NO: 18, wherein the last serine was removed and another serine was appended as starting amino acid), or (a) multimers(s) of these (circular) permutated sequences or fragments thereof. As a consequence, multimers of this modified sequence according to the invention possess essentially the same internal repeating unit as multimers of the non-modified sequence, except for the very first and the very last residue. "Fragments" of these sequences suitable to be employed in accordance with this invention for the generation of the portion P2 may consist of at least 3, preferably of at least 4, more preferably of at least 5, even more preferably of at least 6, still more preferably of at least 8, particularly preferably of at least 10, more particularly preferably of at least 12, even more particularly preferably of at least 14, still more particularly preferably of at least 16, and most preferably of at least 18 consecutive amino acids of the amino acid sequence selected from the group consisting of said SEQ ID NOs: 15 to 22. In another embodiment of the first aspect of the invention, the amino acid repetitive unit sequence is selected from SEQ ID NO: 15 to 22, provided that no more than 6 consecutive amino acid residues are identical, particularly no more than 5 identical consecutive amino acid residues,particularly no more than 4 identical consecutive amino acid residues, particularly no more than 3 identical consecutive amino acid residues.

[0174] In another embodiment of the first aspect of the invention, portion P2 comprises amino acid repetitive units corresponding to SEQ ID NO: 15. In another embodiment of the first aspect of the invention, P2 comprises a plurality of amino acid repetitive units, wherein all the repeats are the same and correspond to sequence SEQ ID NO: 15. In another embodiment of the first aspect of the invention, P2 consists of a plurality of amino acid repetitive units, wherein all the repeats are the same and correspond to sequence SEQ ID NO: 15.

[0175] In another embodiment of the first aspect of the invention, portion P2 comprises a sequence selected from SEQ ID NO: 23-26, 49-50. In another embodiment of the first aspect of the invention, portion P2 consists of a sequence selected from SEQ ID NO: 23-26, 49-50.

[0176] Due to the specific features, portion P2 acquires random coil conformation under physiological conditions.

[0177] As used herein, the term "random coil" relates to any conformation of a polymeric molecule, including amino acid polymers, in which the individual monomeric elements that form said polymeric structure are essentially randomly oriented towards the adjacent monomeric elements while still being chemically bound to said adjacent monomeric elements. In particular, a polypeptide or amino acid polymer adopting / having / forming "random coil conformation" substantially lacks a defined secondary and tertiary structure. The nature of polypeptide random coils and their methods of experimental identification are known to the person skilled in the art and have been described in the scientific literature. Such methods include circular dichroism (CD) spectroscopy. CD spectroscopy represents a light absorption spectroscopy method in which the difference in absorbance of right- and left-circularly polarized light by a substance is measured. The secondary structure of a protein can be determined by CD spectroscopy using far-ultraviolet spectra with a wavelength between approximately 190 and 250 nm. At these wavelengths, the different secondary structures commonly found in polypeptides can be analyzed, since [alpha]-helix, parallel and anti-parallel [beta]-sheet and random coil conformations each give rise to a characteristic shape and magnitude of the CD spectrum. Accordingly, by using CD spectrometry the skilled artisan is readily capable of determining whether an amino acid polymer forms / adopts random coil conformation at physiological conditions. Other established biophysical methods include nuclear magnetic resonance (NMR) spectroscopy, absorption spectrometry, infrared and Raman spectrometry, measurement of the hydrodynamic volume via size exclusion chromatography, analytical ultracentrifugation or dynamic / static light scattering as well as measurements of the frictional coefficient or intrinsic viscosity.

[0178] Moreover, the portion P2 as disclosed herein is thought to be biologically inert, especially with respect to proteolysis in blood plasma, immunogenicity, isoelectric point / electrostatic behavior,binding to cell surface receptors as well as internalization, but still biodegradable, which provides clear advantages over synthetic polymers such as PEG.

[0179] The term "physiological conditions" relates to the biophysical parameters as they are typically valid for higher forms of life and, particularly, in mammals, most preferably human beings. The term "physiological conditions" may relate to the biochemical and biophysical parameters as they are normally found in the body (in particular, in body fluids) of mammals and in particular in humans. Said "physiological conditions" may relate to the corresponding parameters found in the healthy body as well as the parameters as found in sick mammals or human patients. For example, a sick mammal or human patient may have a higher, yet "physiological" temperature condition when said mammal or said human suffers from fever. With respect to "physiological conditions" at which proteins adopt their native conformation / state, the most important parameters are temperature (37°C for the human body), pH (7.35 - 7.45 for human blood), osmolality (280 - 300 mmol / kg H2O), and, if necessary, protein content (66 - 85 g / L serum). Yet, the person skilled in the art is aware that at physiological conditions these parameters may vary, e.g. the temperature, pH, osmolality, and protein content may be different in given body or tissue fluids such as blood, liquor cerebrospinal, peritoneal fluid and lymph It is also envisaged in context of this invention that the random coil conformation as comprised in the above defined portion P2 is maintained in pharmaceutical compositions, like liquid pharmaceuticals. Preferably, "physiological conditions" are to be used in corresponding buffer systems, solvents and / or excipients. Yet, for example in lyophilized or dried compositions (like, e.g. pharmaceutical compositions), it is envisaged that the random coil conformation as comprised in the portion P2 of the biologically active protein is transiently not present and / or cannot be detected. However, said portion P2 will, in accordance with the present protein constructs, adopt / form again its random coil after reconstitution in corresponding buffers / solutions / excipients / solvents. This is for example the case where the polypeptide of the first aspect of the invention has been lyophilized or dried (e.g. in form of a pharmaceutical composition). After reconstitution of such a lyophilized / dried polypeptide construct comprising P1 and portion P2 as defined herein, the random coil part / portion is again present and the corresponding inventive construct can be, e.g., administered to a mammal or human patient in need of medical intervention.

[0180] Birradical X

[0181] According to the first aspect of the invention, X represents a peptide bond, a linker or a nonpeptide bond.

[0182] As used herein, the term “linker” encompasses both peptide or polypeptide sequences (e.g., a synthetic peptide or polypeptide sequence), as well as non-peptide linkers for which their main function is to connect P1 and portion P2. In one embodiment, one or more linkers can be present between P1 and P2. In another embodiment, two or more linkers can be linked in tandem. When multiple linkers are present in a construct of the invention, each one of the linkers can be thesame or different. Generally, linkers provide flexibility to the construct. Linkers are not typically cleaved, thus, in some embodiments, the linker is a non-cleavable linker. In certain embodiments, such cleavage can be desirable, which allows the controlled release of P1 portion having and / or mediating a biological activity. Accordingly, in one embodiment the linker can comprise one or more protease-cleavable sites, which can be located within the sequence of the linker or flanking the linker at either end of the linker sequence.

[0183] In one embodiment, the construct of the invention comprises a non-peptide linker. In another embodiment, the linker consists of a non-peptide linker. Illustrative non-limitative examples of non-peptidic linker comprises, maleimido caproyl (MC), val-cit, MC-val-cit, MC-val-cit-PABC, Mal-PEG2C2, Mal-PEG3C2 Mal-PEG6C2, maleimido propanoyl (MP), methoxyl polyethyleneglycol (MPEG), succinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC), MBS (m-maleimidobenzoyl-N-hydroxysuccinimide ester), 4-succinimidyloxycarbonyl-alpha-methyl-alpha-(2-pyridyldithio)toluene (SMPT), succinimidyl 6-[3-(2-pyridyldithio)-propionamide]hexanoate (LC-SPDP), BMPEO, SPP, succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), N-succinimidyl-S-acetylthioacetate (SATA), N-succinimidyl(4-iodoacetyl)aminobenzonate (SIAB), or any combination thereof.

[0184] In another embodiment, the construct of the invention comprises a peptide linker. In another embodiment, the linker consists of a peptide linker. In one embodiment, the peptide linker comprises at least two amino, at least three, at least four, at least five, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 amino acids. In other aspects, the peptide linker comprises at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, or at least 1 ,000 amino acids. In yet another embodiment, the peptide linker can comprise at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, or 2000 amino acids. The peptide linker can comprise 1-5 amino acids, 1-10 amino acids, 1-20 amino acids, 10-50 amino acids, 50-100 amino acids, 100-200 amino acids, 200-300 amino acids, 300-400 amino acids, 400-500 amino acids, 500-600 amino acids, 600-700 amino acids, 700-800 amino acids, 800-900 amino acids, or 900-1000 amino acids.

[0185] Examples of peptide linkers are well known in the art, for example peptide linkers according to the formula [(Gly)x-(Ser)y]z where x is from 1 to 4, y is 0 or 1 , and z is from 1 to 50 (SEQ ID NO: 31). In one embodiment, the peptide linker comprises the sequence (G)n, where n can be an integer from 1 to 100. In another embodiment, the sequence of the peptide linker is GGGG (SEQ ID NO: 32). The peptide linker can comprise the sequence (GA)n (SEQ ID NO: 33). The peptide linker can comprise the sequence (GGS)n (SEQ ID NO: 34). In other embodiment, the peptide linker comprises the sequence (GGGS)n (SEQ ID NO: 35). In still another embodiment, the peptide linker comprises the sequence (GGS)n(GGGGS)n (SEQ ID NO: 36). In these instances, n can be an integer from 1-100. In other instances, n can be an integer from 1-20, i.e., 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. Examples of linkers include, but are not limited to, SGGSGGS (SEQ ID NO: 37), GGSGGSGGSGGSGGG (SEQ ID NO: 38), GGSGGSGGGGSGGGGS (SEQ ID NO: 39), GGSGGSGGSGGSGGSGGS (SEQ ID NO: 40), or GGGGSGGGGSGGGGS (SEQ ID NO: 41). In other aspects, the linker is a poly-G sequence (GGGG)n, where n can be an integer from 1-100 (SEQ ID NO: 42).

[0186] In another embodiment, the peptide linker is synthetic, i.e., non-naturally occurring. In one embodiment, a peptide linker includes peptides (or polypeptides) (e.g., natural or non-naturally occurring peptides) which comprise an amino acid sequence that links or genetically fuses P1 to P2 which it is not naturally linked or genetically fused in nature. For example, in one embodiment the peptide linker can comprise non-naturally occurring polypeptides which are modified forms of naturally occurring polypeptides (e.g., comprising a mutation such as an addition, substitution or deletion). In another embodiment, the peptide linker can comprise non-naturally occurring amino acids. In another embodiment, the peptide linker can comprise naturally occurring amino acids occurring in a linear sequence that does not occur in nature. In still another embodiment, the peptide linker can comprise a naturally occurring polypeptide sequence.

[0187] In an alternative embodiment of the first aspect of the invention, X is a peptide bond. By “peptide bond” is meant a -C(O)-NH-moiety linking P1 and P2 portions.

[0188] In an alternative embodiment of the first aspect of the invention, X is a non-peptide bond. In the context of the invention, a “non-peptide bond” encompasses any covalent bond other than the amide (-C(O)-NH-) bond. Illustrative non-limitative examples of non-peptide bonds are (Ci-Cw)alkylene-NR1; -(Ci-Cio)alkylene-S-; (Ci-Cw)alkylene optionally substituted by OH, C(O); (C2-Cw)alkenylene; C(Q)(Ci-Cio)alkylene; C(O); and (Ci-Cio)alkylene-S-O-; wherein “alkylene” means any hydrocarbon chain (-CH2-), linear or branched, having from 1 to 10 carbon atoms, and “R1” is a radical selected from hydrogen, (Ci-Cs)alkyl, OH, (Ci-Cs)alkyl substituted by OH. Particularly, -CH2-NH-, -CH2S-, -CH2CH2-, -CH=CH-, -COCH2-, - CH(OH)CH2-, and -CH2SO-. In one embodiment of the first aspect of the invention, the construct of the first aspect of the invention is one wherein X is a non-peptide bond that binds one amino acid located within P1 or P2 sequence with an amino acid located at any position in the other portion. In one embodiment, the construct of the first aspect of the invention is one wherein X is a non-peptide bond that binds an amino acid located at any position in portion P2 with an amino acid located within the sequence of portion P1. In another embodiment, the construct of the first aspect of the invention is one wherein X is a non-peptide bond that binds an amino acid located at a terminal end in portion P2 with an amino acid located within portion P1. In another embodiment, the construct of the first aspect of the invention is one wherein X is a non-peptide bond that binds an amino acid located within portion P2 with an amino acid located within portion P1. In the context of the present invention, the term “within the sequence”, and “within P1 or P2” means that the amino acid is not located at the N- or C-terminal end of the portion P1 or P2.Nucleic acids encoding the constructs of the invention

[0189] The present invention provides a nucleic acid molecule encoding the construct as defined in the first aspect of the invention and in any of the embodiments provided above, comprising the nucleic acid encoding P2 as well as the nucleic acid encoding P1 , and X corresponds to a peptide linker or bond.

[0190] The term "nucleic acid molecule", as used herein, is intended to include nucleic acid molecules such as DNA molecules and RNA molecules. Said nucleic acid molecule may be single-stranded or double-stranded, but preferably is double- stranded DNA. Preferably, said nucleic acid molecule may be comprised in a vector.

[0191] In one embodiment said nucleic acid molecule comprises (i) a nucleic acid sequence encoding a translated amino acid and / or a leader sequence; (ii) a nucleic acid sequence encoding P2; (iii) a nucleic acid sequence encoding P1; and (iv) a nucleic acid sequence that represents or is a translational stop codon. All the embodiments provided under the first aspect of the invention, regarding P1 and P2, are also embodiments of the nucleic acid of the invention.

[0192] The above mentioned "translated amino acid and / or a leader sequence" under (i) may for example be the starting "M", i.e. a methionine derived from a corresponding starting codon, it may also comprise non-translated sequences of an mRNA like the 5' sequence up to a start codon which comprises for example a ribosome binding site. Such a sequence may however also comprise classical leader and / or signal sequences for example for secretion of an expressed protein into the periplasm or into a culture medium. Prokaryotic signal peptides are for example OmpA, MalE, PhoA, DsbA, PelB, Afa, npr, STH. Eukaryotic signal peptides are for example Honeybee melittin signal sequence, acidic glycoprotein gp67 signal sequence, mouse IgM signal sequence, hGH signal sequence.

[0193] Translational stop codons to be employed in the nucleic acid molecule provided herein are well known in the art and are, e.g. codons UAA, UAG or UGA.

[0194] In one embodiment of the nucleic acid molecule as provided herein said nucleic acid molecule parts / segments (ii) and (iii) are interchanged in their position on said nucleic acid molecule encoding for a conjugate, like a drug conjugate or a food conjugate. Such a nucleic acid molecule would comprise the following order of parts / segments: (i) a nucleic acid sequence encoding a translated amino acid and / or a leader sequence; (ii) a nucleic acid sequence encoding P1; (iii) a nucleic acid sequence encoding P2; and (iv) a nucleic acid sequence that represents or is a translational stop codon.

[0195] The nucleic acid molecules as provided herein may also, optionally, comprise, between parts / segments (i) and (ii) and / or between parts / segments (ii) and (iii), a protease and / or a chemical cleavage site and / or a recognition site. Such chemical cleavage sites are well known in the art, and comprise for example specific, individual amino acid sequences. For example,cyanogen bromide or cyanogen chloride cleaves the peptide bond following a Met residue; hydroxylamine cleaves the asparaginyl-glycyl bond; formic acid cleaves Asp-Pro; 2-(2'-nitrophenylsulfenyl)-3- methyl-3-bromoinolenine, 2-iodosobenzoic acid or N-chlorosuccinimide after Trp; 2-nitro-5- thiocyanatobenzoic acid after Cys. It is also envisaged and possible that the residue preceding the Pro / Ala / Ser polypeptide or polypeptide segment may be substituted by Met via site-directed mutagenesis and the resulting fusion protein can then be cleaved by BrCN. Similarly, other amino acid sequences comprising cleavage sites can be introduced into the recombinant fusion protein or its encoding nucleic acid by way of site-directed mutagenesis. Also useful protease recognition / cleavage sites are known in the art. These comprise, but are not limited to: trypsin, chymotrypsin, enterokinase, Tobacco Etch Virus (TEV) protease, PreScission protease, HRV 3C Protease, SUMO Protease, Sortase A, granzyme B, furin, thrombin, factor Xa or self cleavable inteins. Factor Xa hydrolyses the peptide bond at the C-terminal end of the amino acid sequence HeGluGlyArg, which may be inserted between the N-terminal fusion partner and the Pro / Ala / Ser polypeptide or polypeptide segment. A particularly simple method to achieve proteolytic cleavage would be by insertion or substitution of a Lys or Arg side chain at the N-terminal end of the Pro / Ala / Ser polypeptide or polypeptide segment followed by digest with trypsin, which does not cleave within the Pro / Ala / Ser polypeptide or polypeptide segment as long as internal Lys or Arg side chains are avoided.

[0196] In one embodiment of the first aspect of the invention, the nucleic acid molecule encoding P2 portion is selected from: (a) a sequence selected from SEQ ID NO: 34 to 38; (b) the nucleic acid molecule hybridizing, particularly under stringent conditions, to the complementary strand of the nucleotide sequence as defined in (a); (c) the nucleic acid molecule comprising the nucleotide sequence having at least 66.7% identity to the nucleotide sequence as defined in any one of (a) and (b); and (d) the nucleic acid molecule being degenerate as a result of the genetic code to the nucleotide sequence as defined in (a).

[0197] The term "hybridization" or "hybridizes" as used herein may relate to hybridizations under stringent or non-stringent conditions. If not further specified, the conditions are preferably stringent. The setting of suitable conditions is well within the skill of the artisan and can be determined according to protocols described in the art. Thus, the detection of only specifically hybridizing sequences will usually require stringent hybridization and washing conditions such as, for example, 0.1 x saline sodium citrate buffer (SSC), 0.1 % w / v SDS at 65°C or 2 x SSC, 60°C, 0.1 % w / v SDS. Low stringent hybridization conditions for the detection of homologous or not exactly complementary sequences may, for example, be set at 6 x SSC, 1% w / v SDS at 65°C. As is well known, the length of the nucleic acid probe and the composition of the nucleic acid to be determined constitute further parameters of the hybridization conditions.The term “complementary strand”, when referred to a polynucleotide molecule, denotes that the molecule has a complementary base sequence and reverse orientation as compared to a reference sequence, such that it could hybridize with a reference sequence with complete fidelity. It is of note and non-limiting for the present invention that, in accordance with the knowledge of the skilled artisan that the herein described and exemplified peptide portion P2 (or fragments of the same or multimers or circularly permuted versions of the same) may be encoded by different nucleic acid sequences in accordance with the genetic code, which is of degenerate nature, i.e. different nucleotide triplet codons may encode the same amino acid residue. In addition, the terminal residues may differ, depending on the design of a nucleotide sequence cassette according to this invention and on the ligation strategy applied to obtain multimers thereof.

[0198] The nucleotide sequence coding P1 can be obtained, as explained above, from any of the database.

[0199] Vectors and cells

[0200] The present invention also relates to vectors that are conventionally employed in genetic engineering comprising a nucleic acid molecule encoding the biologically active construct of the invention.

[0201] A “vector” is a nucleic acid molecule, preferably self-replicating in an appropriate host, which transfers an inserted nucleic acid molecule into and / or between host cells. The term includes cloning vectors that function primarily for insertion of DNA or RNA into a cell, replication vectors that function primarily for the replication of DNA or RNA, and expression vectors that function for transcription and / or translation of the DNA or RNA. Also included are vectors that provide more than one of the above functions.

[0202] An “expression vector” is a polynucleotide which, when introduced into an appropriate host cell, can be transcribed and translated into a polypeptide(s). An “expression system” usually connotes a suitable host cell comprised of an expression vector that can function to yield a desired expression product.

[0203] In one embodiment the vector is an expression vector and / or a gene transfer or targeting vector. Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses or bovine papilloma virus may be used for delivery of the polynucleotides or vector of the invention into targeted cell populations.

[0204] Regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the lambda PL, lac, trp, tac, ara, phoA, tet orT7 promoters in E. coli. Possible regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells or yeast, are well known to those skilled in the art. They usually comprise regulatory sequences ensuring initiation of transcription and optionally poly-A signals effecting termination of transcription and stabilization of thetranscript. Additional regulatory elements may include transcriptional as well as translational enhancers, and / or naturally associated or heterologous promoter regions. Examples for regulatory elements permitting expression in eukaryotic host cells are the AOXI or GALI promoters in yeast or the CMV, SV40, RSV (Rous sarcoma virus) promoters, CMV enhancer, SV40 enhancer or a globin intron in mammalian and other animal cells. Apart from elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the coding region.

[0205] Methods which are well known to those skilled in the art can be used to construct recombinant vectors (see, for example, the techniques described in Sambrook (1989), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory NY and Ausubel (1989), Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, NY). In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDVI (Pharmacia), pCDM8, pRc / CMV, pcDNAI, pcDNA3, pPICZalpha A (Invitrogen), or pSPORTI (GIBCO BRL). Furthermore, depending on the expression system that is used, leader sequences capable of directing the polypeptide to a cellular compartment or secreting it into the culture medium may be added to the coding sequence of the nucleic acid molecule of the invention.

[0206] To ligate the DNA fragments or genes together, the ends of the DNA must be compatible with each other. In some cases, the ends will be directly compatible after endonuclease digestion. However, it may be necessary to first convert the staggered ends commonly produced after endonuclease digestion to blunt ends to make them compatible for ligation.

[0207] The vectors containing the nucleic acid molecules of the invention can be transfected into the host cell by well-known methods forming part of the general knowledge of the skilled person in the art, and which vary depending on the type of cell. Accordingly, the invention further relates to a cell comprising said nucleic acid molecule or said vector. Illustrative non-limitative examples are calcium chloride transfection or electroporation for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts.

[0208] As a further alternative, the nucleic acid molecules and vectors of the invention can be reconstituted into liposomes for delivery to target cells. The nucleic acid molecule or vector of the invention which is present in the host cell may either be integrated into the genome of the host cell or it may be maintained extra-chromosomally.

[0209] Accordingly, the present invention also relates to a host cell comprising the nucleic acid molecule and / or the vector of this invention.

[0210] A “host cell” includes an individual cell or cell culture which can be or has been a recipient for the subject vectors. Host cells include progeny of a single host cell. The progeny may not necessarily be completely identical (in morphology or in genomic of total DNA complement) to the originalparent cell due to natural, accidental, or deliberate mutation. A host cell includes cells transfected in vivo with a vector of this invention.

[0211] Host cells for the expression of polypeptides are well known in the art and comprise prokaryotic cells as well as eukaryotic cells. The term "prokaryotic" is meant to include bacterial cells while the term "eukaryotic" is meant to include yeast, higher plant, insect and mammalian cells. Illustrative non-limitative examples of suitable cells are E. coli cells, yeast cells, invertebrate cells, CHO cells, CHO-K1 cells, HEK-293 cells, Hela cells, COS-1 monkey cells, melanoma cells such as Bowes cells, mouse L-929 cells, 3T3 cell lines derived from Swiss, Balb-c or NIH mice, BHK or HaK hamster cell lines and the like. Further suitable cell lines known in the art are obtainable from cell depositories, like the American Type Culture Collection (ATCC). Depending upon the host employed in the production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated.

[0212] Synthesis of the biologically active construct of the invention

[0213] All the embodiments provided above, regarding P1 and P2 are also embodiments of the process for preparing the biologically active construct of the invention.

[0214] The biologically active construct of the invention may be produced by recombinant DNA technology, e.g. by cultivating a cell comprising the described nucleic acid molecule or vector of the invention, and isolating said biologically active construct from the culture.

[0215] The transformed hosts can be grown in fermenters and cultured according to techniques known in the art to achieve optimal cell growth. In a further embodiment, the present invention relates to a process for the preparation of a construct as defined in the first aspect of the invention and any of the embodiments provided above, comprising cultivating a cell of the invention under conditions suitable for the expression of the biologically active construct and isolating it from the cell or the culture medium.

[0216] The biologically active construct of the invention can be isolated from the growth medium, cellular lysates or cellular membrane fractions. The isolation and purification of the expressed polypeptides of the invention may be performed by any conventional means, including ammonium sulphate precipitation, affinity columns, column chromatography, gel electrophoresis and the like and may involve the use of monoclonal or polyclonal antibodies directed, e.g., against a tag fused with the biologically active protein of the invention. For example, the protein can be purified via the Strep-tag II using streptavidin affinity chromatography.

[0217] Alternatively, the process comprises the conjugation of a portion P1 corresponding to AAT (as defined above) and portion P2 (including the repetitive units including Pro, Ala, and Ser).

[0218] The obtaining of AAT, as it has been explained above, encompasses from commercial AATs to the expression of recombinant and variants of AAT. As explained above, the design of the expression vector forms part of the routine activities of the skilled person in the art (selection ofnucleotide AAT sequence in public databases, appropriate vector, regulatory elements and conditions).

[0219] The obtaining of portions P2 can be performed by expressing a vector including the corresponding encoding nucleotide sequence.

[0220] There are well-known protocols in the state of the art disclosing alternative ways of conjugating peptides. In one embodiment of the invention, the conjugation occurs between an amino acid located in P1 and another located in P2, such as one of them bears a nucleophilic side-chain and the other an electrophilic side-chain.

[0221] Oxime / Hydrazone conjugation involves the formation of covalent bonds between aldehydes or ketones and aminooxy or hydrazide groups, resulting in stable oxime or hydrazone linkages. This reaction is particularly useful for bioconjugation due to its high specificity and stability. The reaction typically occurs between an aldehyde or ketone and an aminooxy or hydrazide group. The resulting oxime or hydrazone bond is stable and can be formed under mild conditions. The reaction is bioorthogonal, meaning it can occur in the presence of other functional groups without interference. It is also highly specific and can be performed in aqueous solutions.

[0222] Cysteine-Based conjugation is based on Cys residues which, due to their nucleophilic thiol groups, can undergo a variety of reactions. Common methods include using electrophiles to react with the thiol group of cysteine. Illustrative non-limitative examples of suitable electrophiles are (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides, such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups; and (iv) disulfides, including pyridyl disulfides, via sulfide exchange, maleimides, iodoacetamides, and pyridyl disulfides. This results in the formation of stable thioether bonds. The same synthetic approach with Lys can be followed due to its nucleophilic amine group.

[0223] In one embodiment, the conjugation occurs between any amino acid of portion P2 and a Cys residue forming part of P1 portion.

[0224] In one embodiment, the process comprises (1) the activation of N-terminus or the C-terminus of P2 with a commercially available electrophilic reagent as defined above and, (2) the coupling of the activated N-or C-terminal to a thiol group forming part of P1. In this manner uniform drug conjugates can be easily obtained.

[0225] In one embodiment, the process comprises the activation of P2 at its N-terminus via reaction with a commercially available electrophilic reagent as defined above, such as one providing a succinimide group (for instance via reaction with bromoacetic acid-NHS ester), and the subsequent conjugation by mixing the activated N-terminus P2 and the Cys forming part of P1 at approximately equimolar amount, resulting in a thioether bond between the two molecules. In another embodiment the process, when P2 includes one or more separating amino acids between two repetitive units, and one of these separating amino acids is Lys or His, comprises:the protection of the N-terminal end of P2 (for example by cyclization of glutamine to pyroglutamic acid), the activation of the side-chain of the His or Lys (for example a commercially available electrophilic reagent as defined above, such as one providing a succinimide group (for instance via reaction with bromoacetic acid-NHS ester), and finally the subsequent conjugation by mixing the activated P2 with P1 at approximately equimolar ratio, resulting in a thioether bond between the two molecules.

[0226] As an alternative to a single site-specific conjugation, P1 may be equipped with additional side chains, at the N- or C-terminus or internally, suitable for chemical modification such as lysine residues with their e-amino groups, cysteine residues with their thiol groups, or even non-natural amino acids, allowing the conjugation of multiple small molecules using, for example, NHS ester or maleimide active groups in P2.

[0227] Other approaches include that the N-terminal amino group can be chemically coupled with a wide variety of functional groups such as aldehydes and ketones to form Schiff bases (which may be reduced to amines using sodium borohydride or sodium cyanoborohydride, for example) or to activated carbonic acid derivatives (anhydrides, chlorides, esters and the like, to form amides) or to other reactive chemicals such as isocyanates, isothiocyanates, sulfonyl chlorides etc. Also, the N- terminus of the amino acid can first be modified with a suitable protective group, for example an acetyl group, a BOC group or an FMOC group (Jakubke (1996) Peptide. Spektrum Akdemischer Verlag, Heidelberg, Germany). Furthermore, the amino terminus may be protected by a pyroglutamyl group, which can form from an encoded Gin amino acid residue preceding the Pro / Ala / Ser polypeptide or polypeptide segment. After activation of the C-terminal carboxylate group, e.g. using the common reagents EDC (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide) and NHS, site-specific coupling to the C-terminus of the protected random coil polypeptide can be achieved if the other component carries a free amino group, for example.

[0228] In one embodiment of the first aspect of the invention, optionally in combination with any of the embodiments provided above or below, the construct is selected from the group consisting of: (i) SEQ ID NO. 43 conjugated at Cys232 to Alai of SEQ ID NO: 51 , via Ac (AAT_P2_200), (ii) SEQ ID NO. 44 conjugated at Cys232 to Alai of SEQ ID NO. 52, via Ac (AAT_P2_400), (iii) SEQ ID NO. 45 conjugated at Cys232 to Alai of SEQ ID NO. 53, via Ac (AAT_P2_600), (iv) SEQ ID NO. 46 conjugated at Cys232 to Lys206 of SEQ ID NO. 54, via Ac (AAT_P2_(2x200)), (v) SEQ ID NO. 47 conjugated at Cys232 to Lys206 of SEQ ID NO. 55, via Ac (AAT_P2_(2x200)), and

[0229] (vi) SEQ ID NO. 48 conjugated at Cys232 to Lys205 of SEQ ID NO. 56, via Ac (AAT_P2_(2x200)). See also Fig. 8.Pharmaceutical Compositions

[0230] The present invention provides pharmaceutical compositions comprising the construct of the invention together with one or more pharmaceutically acceptable excipients or carriers. All the embodiments provided under the first aspect of the invention are also embodiments of the pharmaceutical composition as defined in the sixth aspect of the invention.

[0231] As used herein, the term “pharmaceutical” includes veterinary applications of the invention. The construct of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the construct is combined in admixture with a pharmaceutically acceptable carrier vehicle, such as aqueous solutions, buffers, solvents and / or pharmaceutically acceptable suspensions, emulsions, stabilizers or excipients. Examples of nonaqueous solvents include propylethylene glycol, polyethylene glycol and vegetable oils. Formulations of the pharmaceutical compositions are prepared for storage by mixing the active construct having the desired degree of purity with optional physiologically acceptable carriers, excipients (e.g., sodium chloride, a calcium salt, sucrose, or polysorbate) or stabilizers (e.g., sucrose, trehalose, raffinose, amino acids (such as arginine, glycine or histidine), or a calcium salt), as described in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980), in the form of lyophilized formulations or aqueous solutions.

[0232] In one embodiment, the pharmaceutical composition may be supplied as a lyophilized powder to be reconstituted prior to administration. In another embodiment, the pharmaceutical composition may be supplied in a liquid form, which can be administered directly to a patient. In another embodiment, the composition is supplied as a liquid in a pre-filled syringe for administration of the composition. In another embodiment, the composition is supplied as a liquid in a pre-filled vial that can be incorporated into a pump.

[0233] The pharmaceutical compositions can be administered by any suitable means or route, including intradermal, intraperitoneal, intrapulmonary, intranasal (for example using a nebuliser or inhaler device), transdermal, transmucosal, oral, vaginal, rectal, intracerebral, intracranial, intraspinal, intraorbital, intracapsular, intrathecal, intravitreal, intraarticular, topical, subcutaneously, subcutaneously by infusion pump, intramuscularly, intravenously, or via the pulmonary route. It will be appreciated that the preferred route will vary with the disease and age of the recipient, and the severity of the condition being treated. Alternatively, the alpha-1 antitrypsin may be administered locally during surgical intervention.

[0234] In another embodiment, the pharmaceutical composition, in liquid form or after reconstitution (when supplied as a lyophilized powder), is capable of being detected in body fluids for at least about 72 hours, or at least about 96 hours, or at least about 120 hours, or at least about 7 days after administration of the alpha 1-antitrypsin pharmaceutical composition to a subject in need. It is specifically contemplated that the pharmaceutical compositions of the foregoing embodimentsin this paragraph can be formulated to include one or more excipients, buffers or other ingredients known in the art to be compatible with the intended administration.

[0235] The compositions of the invention may be formulated using a variety of excipients. Suitable excipients include microcrystalline cellulose (e.g. Avicel PH102, Avicel PH101), polymethacrylate, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) (such as Eudragit RS-30D), hydroxypropyl methylcellulose (Methocel K100M, Premium CR Methocel K100M, Methocel E5, Opadry®), magnesium stearate, talc, triethyl citrate, aqueous ethylcellulose dispersion (Surelease®), and protamine sulfate. The slow release agent may also comprise a carrier, which can comprise, for example, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents. Pharmaceutically acceptable salts can also be used in these slow release agents, for example, mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates, as well as the salts of organic acids such as acetates, proprionates, malonates, or benzoates. The composition may also contain liquids, such as water, saline, glycerol, and ethanol, as well as substances such as wetting agents, emulsifying agents, or pH buffering agents.

[0236] In another embodiment, the compositions of the present invention are encapsulated in liposomes, which have demonstrated utility in delivering beneficial active agents in a controlled manner over prolonged periods of time. Liposomes are closed bilayer membranes containing an entrapped aqueous volume. Liposomes may also be unilamellar vesicles possessing a single membrane bilayer or multilamellar vesicles with multiple membrane bilayers, each separated from the next by an aqueous layer. The structure of the resulting membrane bilayer is such that the hydrophobic (non-polar) tails of the lipid are oriented toward the center of the bilayer while the hydrophilic (polar) heads orient towards the aqueous phase. In one embodiment, the liposome may be coated with a flexible water soluble polymer that avoids uptake by the organs of the mononuclear phagocyte system, primarily the liver and spleen. Suitable hydrophilic polymers for surrounding the liposomes include, without limitation, PEG, polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline, polyhydroxypropylmethacrylamide, polymethacrylamide, polydimethylacrylamide, polyhydroxypropylmethacrylate, polyhydroxethylacrylate, hydroxymethylcellulose hydroxyethylcellulose, polyethyleneglycol, polyaspartamide and hydrophilic peptide sequences. Liposomes may be comprised of any lipid or lipid combination known in the art. For example, the vesicle-forming lipids may be naturally-occurring or synthetic lipids, including phospholipids, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidylserine, phasphatidylglycerol, phosphatidylinositol, and sphingomyelin as disclosed in U.S. Pat. Nos.

[0237] 6,056,973 and 5,874,104. The vesicle-forming lipids may also be glycolipids, cerebrosides, or cationic lipids, such as 1,2-dioleyloxy-3-(trimethylamino) propane (DOTAP); N-[1-(2,3,-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE); N-[1[(2,3,-dioleyloxy)propyl]-N,N-dimethyl-N-hydroxy ethylammonium bromide (DORIE); N-[1-(2,3-dioleyloxy)propyl]-N,N, N-trimethylammonium chloride (DOTMA); 3 [N — (N',N -dimethylaminoethane) carbamoly] cholesterol (DC-Chol); or dimethyldioctadecylammonium (DDAB). Cholesterol may also be present in the proper range to impart stability to the vesicle. For liquid formulations, a desired property is that the formulation be supplied in a form that can pass through a 25, 28, 30, 31, 32 gauge needle for intravenous, intramuscular, intraarticular, or subcutaneous administration. In another embodiment, a desired property is that the formulation be supplied in a form that can be nebulized into an aerosol of suitable particle size for inhalation therapy.

[0238] Osmotic pumps may be used as slow release agents in the form of tablets, pills, capsules or implantable devices. Osmotic pumps are well known in the art and readily available to one of ordinary skill in the art from companies experienced in providing osmotic pumps for extended release drug delivery. Examples are ALZA's DUROS™; ALZA's OROS™; Osmotica Pharmaceutical's Osmodex™ system; Shire Laboratories' EnSoTrol™ system; and Alzet™. Patents that describe osmotic pump technology are U.S. Pat. Nos. 6,890,918; 6,838,093; 6,814,979; 6,713,086; 6,534,090; 6,514,532; 6,361,796; 6,352,721; 6,294,201; 6,284,276; 6,110,498; 5,573,776; 4,200,0984; and 4,088,864, the contents of which are incorporated herein by reference. One skilled in the art, considering both the disclosure of this invention and the disclosures of these other patents could produce an osmotic pump for the extended release of the polypeptides of the present invention.

[0239] Syringe pumps may also be used as slow release agents. Such devices are described in U.S. Pat. Nos. 4,976,696; 4,933,185; 5,017,378; 6,309,370; 6,254,573; 4,435,173; 4,398,908; 6,572,585; 5,298,022; 5,176,502; 5,492,534; 5,318,540; and 4,988,337, the contents of which are incorporated herein by reference. One skilled in the art, considering both the disclosure of this invention and the disclosures of these other patents could produce a syringe pump for the extended release of the compositions of the present invention.

[0240] As it is shown below, in Table E, incorporating portion P2 into hAAT not only avoids any reduction in the bioavailability of native AAT, but unexpectedly results in a marked improvement when the construct was sc administered.

[0241] Thus, in one embodiment the invention provides a subcutaneous pharmaceutical composition comprising one or more biologically active constructs, vector or the cell as defined along the specification, together with one or more pharmaceutically acceptable excipients or carriers. In another embodiment the invention provides a subcutaneous pharmaceutical composition comprising one or more biologically active constructs, together with one or more pharmaceutically acceptable excipients or carriers, wherein the one or more constructs are the same or different and are selected from:

[0242] (i) SEQ ID NO. 43 conjugated at Cys232 to Alai of SEQ ID NO: 51 , via Ac (AAT_P2_200),(ii) SEQ ID NO. 44 conjugated at Cys232 to Alai of SEQ ID NO. 52, via Ac (AAT_P2_400), (iii) SEQ ID NO. 45 conjugated at Cys232 to Alai of SEQ ID NO. 53, via Ac (AAT_P2_600), (iv) SEQ ID NO. 46 conjugated at Cys232 to Lys206 of SEQ ID NO. 54, via Ac (AAT_P2_(2x200)), (v) SEQ ID NO. 47 conjugated at Cys232 to Lys206 of SEQ ID NO. 55, via Ac (AAT_P2_(2x200)), and

[0243] (vi) SEQ ID NO. 48 conjugated at Cys232 to Lys205 of SEQ ID NO. 56, via Ac (AAT_P2_(2x200)). In another embodiment the invention provides a subcutaneous pharmaceutical composition of wherein the one or more biologically active constructs are the same or different and are selected from:

[0244] (a) SEQ ID NO. 45 conjugated at Cys232 to Alai of SEQ ID NO. 53, via Ac (AAT_P2_600), (b) SEQ ID NO. 46 conjugated at Cys232 to Lys206 of SEQ ID NO. 54, via Ac (AAT_P2_(2x200)), (c) SEQ ID NO. 47 conjugated at Cys232 to Lys206 of SEQ ID NO. 55, via Ac (AAT_P2_(2x200)), and

[0245] (d) SEQ ID NO. 48 conjugated at Cys232 to Lys205 of SEQ ID NO. 56, via Ac (AAT_P2_(2x200)), together with one or more pharmaceutically acceptable excipients or carriers.

[0246] In another embodiment, the subcutaneous pharmaceutical composition of any of the preceding is in lyophilized form. In an alternative embodiment, the subcutaneous pharmaceutical composition is in liquid form.

[0247] The term "subcutaneous," as used herein, refers to below the skin (e.g., in the connective tissue underlying the dermis and above the facia of the muscle tissue).

[0248] Subcutaneous administration, therefore, refers to the delivery of a desired dosage of AAT below the skin via a medication delivery device. The medication delivery device can penetrate the epidermis of the individual to be treated, and results in introducing the desired dosage of AAT into the tissues of the individual. The delivery device of the present invention may include, but is not limited to any traditional hypodermic needle injectors, air-powered needle-less injectors, jet injectors, or gas-pressured needle-less injectors.

[0249] In one embodiment, the subject is a human, wherein the site of subcutaneous administration includes, but is not limited to supra scapular, upper chest, upper thigh, and combinations thereof. One factor that may be considered when determining a therapeutically or prophylactically effective amount of the construct of the invention for subcutaneous administration is the concentration of functionally active AAT expressed in a biological compartment of the subject, such as, for example, in the lower respiratory tract or the epithelial lining fluid (ELF) of the subject. Another factor that also may be considered when determining a therapeutically or prophylacticallyeffective amount of the construct for subcutaneous administration is its pharmacology (e.g., pharmacokinetics).

[0250] It is to be noted that dosage values may vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens can be adjusted over time according to the individual need and the professional judgment of the caregiver, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the invention.

[0251] Subcutaneous dosage regimens may be adjusted to provide the optimum therapeutic or prophylactic response. For example, a single subcutaneous bolus may be administered, several divided doses may be administered subcutaneously over time, or the dose may be proportionally reduced or increased as indicated by the requirement of the therapeutic or prophylactic situation. Further, one or more subcutaneous doses can be administered as part of a regimen comprising other modes of AAT administration including, but not limited to, intravenous administration. The dose and frequency of subcutaneous administration of AAT may be tailored to the individual subject. Accordingly, both the dose and frequency can vary.

[0252] Doses may be subcutaneously administered at such frequencies and for as long as is deemed necessary and safe, as is readily ascertained by standard tests by the caregiver (e.g., physician or veterinarian) depending upon the specific disorder or disease being treated.

[0253] In one embodiment, the dose is subcutaneously administered at least once per a time unit, illustratively, at least once, twice, three times, four times, five times, six times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, and so on per a time unit. In another embodiment, the time unit is an hour, a day, a week, every two weeks, every three weeks, a month, every 1, 2, 3, 4, 5, and 6 months, etc.

[0254] Where appropriate, the dosages and frequencies of subcutaneous administration may be adjusted upward or downward. In other embodiments, subcutaneous administration may be performed before, simultaneous with, or after other modes of AAT administration such as, for example, intramuscular or intravenous administration.

[0255] The construct of the invention can be administered subcutaneously for a variety of applications including human and veterinary therapies, either alone or in combination with one or more reagents, e.g., a reagent capable of enhancing the pharmacokinetics and / or pharmacodynamics of the subcutaneously administered construct.

[0256] The route of administration and the amount of the one or more reagents administered can vary according to various subject variables including size, weight, age, disease severity, and responsiveness to therapy. Methods for determining the appropriate route of administration and dosage of the one or more reagents can generally be determined on a case-by-case basis. Suchdeterminations are routine to one of ordinary skill in the art (see, for example; Harrison's Principles of Internal Medicine, 11th Ed., 1987).

[0257] In one embodiment, the one or more reagents is a hydrolase such as, for example, a glycosidase. Illustrative non-limiting example of a glycosidases includes hyaluronidase, a-amylase, p-amylase, keratanase, dextranase, endoglycoceramidase II, chitosanase, chitinase, thioglucosidase, pectinase, pectolyase, lysozyme, neuraminidase, a-glucosidase, p-glucosidase, a-galactosidase, P-galactosidase, a-mannosidase, invertase, trehalase, amyloglucosidase, p-glucuronidase, hyaluronidase, cellulase, hesperidinase, pullulanase, a-N-acetylgalactosaminidase, a-L-fucosidase, p-N-acetylglucosaminidase, p-N-acetylhexosaminidase, p-glucanase, laminarinase, isoamylase, inulinase, xylanase, agarase, endoglycosidase H, endoglycosidase F2, endoglycosidase F3, endoglycosidase H, endoglycosidase F1, O-glycosidase, Fpg protein, NADase, diastase, and xylanase.

[0258] In some embodiments, the glycosidase is a hyaluronidase. For example, the hyaluronidase can be an enzyme that is capable of cleaving p-N-acetylhexosamine-(1-4)-glycosidic bonds in hyaluronic acid, chondroitin, and / or chondroitin sulfates. For example, the hyaluronidase can be administered as an adjuvant to increase the absorption of the construct of the invention thereby enhancing its pharmacokinetics and / or pharmacodynamics. It is believed that hyaluronidase can act as a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Hyaluronidase at least can hydrolyze hyaluronic acid by splitting the glucosaminidic bond between C1 of the glucosamine moiety and C4 of glucuronic acid. It is believed that this can temporarily decrease the viscosity of the cellular cement and promote diffusion of injected fluids or of localized transudates or exudates, thus facilitating their absorption. The rate of diffusion can be proportionate to the amount of enzyme, and the extent can be proportionate to the volume of solution. Knowledge of the mechanisms involved in the disappearance of injected hyaluronidase is limited, however, it is believed that the blood of a number of mammalian species brings about the inactivation of hyaluronidase.

[0259] The specific dosage appropriate for administration can be readily determined by one of ordinary skill in the art and / or according to the factors discussed herein. In addition, one of ordinary skill in art will recognize that the estimates for appropriate dosages in humans can be extrapolated from determinations of the level of enzymatic activity of the enzyme in vitro and / or dosages effective in animal studies.

[0260] A number of hyaluronidase injections are known such as, for example, formulations marketed as Amphadase™ (150 units / mL injectable solution), Hydase™ (150 units / mL injectable solution), Hylenex™ (150 units / mL injectable solution), Vitrase™ (200 units / mL injectable solution), and Vitrase™ (6200 units injection). For example, according to one manufacturer, Amphadase™(Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, CA) is a preparation of purified bovine testicular hyaluronidase supplied as a sterile, colorless, ready for use solution, and absorption and dispersion of other injected drugs may be enhanced by adding 50-300 Units Amphadase™, typically 150 U Amphadase™, to the injection solution. Each vial of Amphadase™ contains 150 USP units of hyaluronidase per mL with 8.5 mg sodium chloride, 1 mg edetate disodium, 0.4 mg calcium chloride, monobasic sodium phosphate buffer, and not more than 0.1 mg thimerosal (mercury derivative). The ready for use solution is clear and colorless with an approximate pH of 6.8 and an osmolality of 295 to 355 mOsm.

[0261] The construct of the invention may be subcutaneously administered to a subject in a composition comprising the construct together with an effective amount of a hyaluronidase, wherein the effective amount is sufficient to increase absorption, dispersion, or both of construct. In one embodiment, the hyaluronidase is administered separately, simultaneously or consecutively with the construct or composition of the invention. In another embodiment, the hyaluronidase is administered contemporaneously with the construct, wherein the composition further comprises the hyaluronidase. In some embodiments, the hyaluronidase is administered contemporaneously with construct, wherein the composition comprising the construct is administered at a site different from the site of administration of the hyaluronidase.

[0262] In other embodiments, the present specification illustrates a pharmaceutical composition comprising the construct of the invention, a hyaluronidase, and a pharmaceutically acceptable carrier, wherein the composition is suitable for subcutaneous administration to a subject. In one embodiment, the subject is a human. The pharmaceutical composition can be in the form of a lyophilized formulation.

[0263] The construct as defined in the first aspect of the invention, can be lyophilized in a container in which its reconstitution is to be carried out in order to avoid a transfer step. Generally, lyophilization will result in a lyophilized formulation in which the moisture content thereof is less than about 5%, and preferably less than about 3%. And, typically, when it is time to subcutaneously administer the construct to the subject, the lyophilized formulation may be reconstituted with a suitable diluent to achieve the desired AAT concentration. Reconstitution generally takes place at a temperature of about 25°C to ensure complete hydration, although other temperatures may be employed as desired. The time required for reconstitution will depend, e.g., on the type of diluent, amount of excipient(s) and protein. Exemplary diluents include, but are not limited to, sterile water, bacteriostatic water for injection (BWFI), a pH buffered solution (e.g. phosphate-buffered saline), sterile saline solution, and Ringer's solution or dextrose solution. The diluent optionally contains a preservative. The amount of preservative employed is determined by assessing different preservative concentrations for compatibility with the protein and preservative efficacy testing.The reconstituted formulation is to be administered to the subject, such as, for example, a human, in accordance with known methods, by subcutaneous (i.e. beneath the skin) administration. For such purposes, the formulation may be injected using a syringe. However, other devices for administration of the formulation are available such as injection devices (e.g. the Inject-case™ and Genject™ devices); injector pens (such as the GenPen™); needleless devices (e.g. MediJector™ and BioJector™); and subcutaneous patch delivered systems. The protein may be administered as the sole treatment or in conjunction with other drugs or therapies. Subcutaneous placement of a winged infusion set, for example, can be used to minimize repeated needle injections.

[0264] Therapeutic uses

[0265] The present invention provides in a further aspect the biologically active construct, vector, or pharmaceutical composition as defined in any of the aspects and embodiments provided above, for use as a medicament.

[0266] As explained above, the role of AAT as anti-inflammatory, anti-bacterial and immunomodulatory agent has been widely reported in the prior art (see Janciauskiene S. et al., supra, Bergin D. A. etal., supra). The construct of the invention bearing the AAT portion (P1), which, as shown below is stable but also active when conjugated with P2, can also find applications as anti-inflammatory, anti-bacterial and immunomodulatory agent. Therefore, the invention also provides the use of the biologically active construct, vector, or pharmaceutical composition as defined in any of the aspects and embodiments provided above in the treatment or prevention of inflammation, infection and in immunomodulation.

[0267] In another aspect, the present invention provides the use of the biologically active construct, vector, or pharmaceutical composition as defined in any of the aspects and embodiments provided above in the treatment or prevention of a1 -antitrypsin-deficiency disease.

[0268] In the context of the invention, the terms “a1 -antitrypsin-deficiency disease”, “AATD” and “a1-antitrypsin-deficiency disease” have the same meaning, can be used interchangeably and encompasses diseases or pathological conditions wherein the AAT’s expression level and / or activity is / are reduced, either systemically or locally within a specific tissue or anatomical site, even if overall or circulating AAT levels are within the normal range. There are well-known methods for those skilled in the art suitable for determining AAT’s level, in terms of expression level and activity. Illustrative non-limitative examples of such protocols are provided below, in the section of “Examples”. Illustrative, non-limitative examples of these diseases are lung disease such as chronic obstructive pulmonary disease (COPD) (such as emphysema), liver disease, vascular disease (e.g., intracranial aneurysms, arterial fibromuscular dysplasia, severe bleeding disorders, and hypertension), panniculitis, eye disease (e.g., anterior uveitis), systemic necrotizing vasculitis, and granulomatosis with polyangiitis.In one embodiment, the biologically active construct, vector or pharmaceutical composition is used in the treatment of diabetes.

[0269] In one embodiment, the biologically active construct, vector or pharmaceutical composition is used in the treatment of ischemic reperfusion injury.

[0270] In one embodiment, the biologically active construct, vector or pharmaceutical composition is used in the treatment of organ or non-organ (such as prothesis) transplant rejection.

[0271] In one embodiment, the biologically active construct, vector or pharmaceutical composition is used in the treatment of graft versus host disease (GvHD).

[0272] In one embodiment, the biologically active construct, vector or pharmaceutical composition is used in the treatment of an infection. Particularly the infection comprises a bacterial, viral, fungal or parasitic infection.

[0273] In one embodiment, the biologically active construct, vector or pharmaceutical composition is used in the treatment of a lung condition or lung infection. Particularly, the lung condition comprises an inflammatory lung disease comprising chronic pulmonary obstructive disease (COPD) or emphysema or other inflammatory lung disease.

[0274] Particularly, the present invention provides the biologically active construct, vector or pharmaceutical composition as defined above, for use in the treatment or prevention of one or more of rheumatoid arthritis, lupus, systemic lupus erythematosus (SLE), chronic inflammation of coronary arteries, Crohn's Disease, inflammatory bowel disease (IBD), ulcerative colitis, gastroduodenitis, Celiac disease, Sprue, Celiac sprue dermatitis, chronic pulmonary obstructive disease (COPD), emphysema, systemic inflammatory response syndrome (SIRS), asthma, Sjogren's syndrome, scleroderma, dermatomyositis, polymyositis, Reiter's syndrome, Behcet's disease, multiple sclerosis, myasthenia gravis, or encephalomyelitis, Hashimoto's thyroiditis, Graves' Disease, uveitis, Alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, Bullous pemphigoid, cardiomyopathy, chronic inflammatory demyelinating polyneuropathy, fibromyalgia-fibromyositis, Glomerulonephritis, Guillain-Barre, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA neuropathy, Juvenile arthritis, Lichen planus, Meniere's disease, mixed connective tissue disease, Myasthenia gravis, Pemphigus vulgaris, Pernicious anemia, Polyarteritis nodosa, Polychrondritis, Polyglandular syndromes, Polymyalgia rheumatic, Polymyositis and dermatomyositis, Primary agammaglobulinemia, Primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynauld's phenomenon, Reiter's syndrome, Sarcoidosis, Scleroderma, Stiff-man syndrome, Takayasu arteritis, Temporal arteristis / giant cell arteritis, dermatitis herpetiformis vasculitis, Vitiligo, Wegener's granulomatosis, inflammatory osteolysis, osteoporosis, chronic inflammation (e.g. from chronic viral or bacterial infections), encephalitis, spinal nerve or cord injury, tenosynovitis, psoriasis (e.g., plaque psoriasis, pustular psoriasis,erythrodermic psoriasis, guttate psoriasis or inverse psoriasis), liver cirrhosis, acute-on-chronic liver failure, pulmonary fibrosis, undifferentiated arthropathy, undifferentitated spondyloarthropathy, fibrosarcoma, myxo sarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, Kaposi's sarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, rhabdosarcoma, colorectal carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, melanoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, myeloma, lymphoma, leukemia, sepsis, atherosclerosis, Alzheimer's disease, muscular dystrophy, Down’s syndrome, stroke, neurodegenerative disorders, preventing or treating GVHD, treating a subject undergoing an organ or non-organ (such as prothesis) transplant comprising a heart, lung, intestinal, liver, pancreas, kidney, soft tissue, facial component, pancreatic islet cells, stem cells, bone marrow cells, or corneal epithelial transplants, before, during or after plastic, cosmetic surgery or reconstructive surgery, (e.g. elective, burns; traumatic injuries, mastectomy, breast implants, congenital abnormalities, such as cleft palates or cleft lips; developmental abnormalities), wound healing, osteoarthritis, acute respiratory distress syndrome, bronchiectasis, retinopathies (e.g. diabetic retinopathy), age macular degeneration, drug induced liver injury (including ILICI (immune-mediated liver injury from immune checkpoint inhibitors), CHILI (Checkpoint Inhibitor-induced Liver Injury), pregnancy disorders (e.g. spontaneous premature birth, abortion, gestational hypertension), myocardial ischemia, chronic systemic arterial and venous hypertension, pulmonary arterial and venous hypertension, congenital heart disease (with and without intracardiac shunting), valvular heart disease, idiopathic dilated cardiomyopathy, infectious and non-infectious myocarditis, stress cardiomyopathy, septic cardiomyopathy, atrial and ventricular arrhythmias, endocarditis, pericarditis, ventricular remodeling, concentric hypertrophy, eccentric hypertrophy, renal disorders and failure, or gout.

[0275] While the constructs of the invention can be used to treat the patients described herein, any of the constructs of the invention, vectors and pharmaceutical compositions can be combined with at least one additional pharmaceutical agent and / or co-administered to a patient described herein. The co-administration can be achieved by combining the agents in a single formulation, in which case the agents would be administered at the same time and by the same route. Coadministration can also be achieved when the agents are formulated differently (e.g., one in an intravenous formulation and one in an oral preparation) and administered at the same or differenttimes (e.g., sequentially and within a time frame sufficient to treat the patient). Co-administration of more than one agent or more than one type of agent (e.g., an AAT-related agent and an antiinflammatory agent) may bring about normoglycemia sooner or produce a normoglycemic state that persists longer after cessation of treatment than with either agent alone (no particular benefit is required as a feature of the invention, however).

[0276] Combinations of agents useful in the methods described herein include the combination of an AAT-related agent and: an anti-inflammatory agent, such as a non-steroidal anti-inflammatory agent (or NSAID); an antagonist of TNFa; an anti-TNFa antibody; an antagonist of an inflammatory cytokine; agonist of a glucagon-like peptide (GLP) receptor or an agonist of an exendin receptor; an agonist of CD3; or a glycosidase, as defined above, including hyaluronidase.

[0277] In certain embodiments, the subject is a mammal. In some embodiments, the mammal is a human. In yet other embodiments, the subject is a pregnant female or young child. In other embodiments, the subject is a pet, a domesticated animal or livestock.

[0278] In one embodiment, the biologically active construct, nucleic acid, vector, cell or the pharmaceutical composition of the invention is administered by subcutaneous or intravenous route, particularly by subcutaneous route. In another embodiment, the biologically active construct, nucleic acid, vector, cell or the pharmaceutical composition of the invention is administered by subcutaneous route in combination with hyaluronidase. In another embodiment, the biologically active construct, nucleic acid, vector, cell or the pharmaceutical composition of the invention is administered by subcutaneous route in combination with hyaluronidase, being administered consecutively, simultaneously or separately.

[0279] Unit Dosage Form

[0280] In another aspect the invention provides a unit dosage form including the construct, nucleic acid molecule, vector, cell or pharmaceutical composition as defined throughout the specification. A unit dosage form refers to a single, pre-measured quantity of a drug designed for administration as one dose to a patient. It ensures accuracy, convenience, and consistency in dosing.

[0281] It contains the amount of active ingredient intended for one administration, thus facilitating patient compliance and reduces dosing errors.

[0282] Illustrative non-limitative examples of unit dosage forms for SC route are: prefilled syringes, cartridges for pen Injectors, single-dose vials, and autoinjectors.

[0283] The skilled person in the art, using their general knowledge, may manufacture the desired unit dosage form including the pharmaceutical composition of the invention.

[0284] KitsIn another aspect, the invention provides a kit to facilitate the use of the construct of the invention. Particularly, the invention provides a kit comprising the biologically active construct, the nucleic acid, the vector, or the cell as defined in any of the above aspects and embodiments, or the unit dosage form of the invention, together with auxiliary means and instructions for the preparation of the construct; or, alternatively, the kit comprises P1 and P2 amino acidic portions in separate containers together with auxiliary means and instructions for preparing the construct.

[0285] Suitable containers include, for example, bottles, vials (e.g. dual chamber vials), syringes (such as dual chamber syringes) and test tubes. The container may be formed from a variety of materials such as glass or plastic. The container holds the composition(s) or lyophilized formulations and the label on, or associated with, the container may indicate directions for reconstitution and / or use. For example, the label may indicate that the lyophilized formulation is reconstituted to protein concentrations as described above. The label may further indicate that the formulation is useful or intended for subcutaneous administration. The container holding the formulation may be a multi-use vial, which allows for repeat administrations (e.g. from 2-6 administrations) of the reconstituted formulation. The article of manufacture may further comprise a second container comprising a suitable diluent (e.g. BWFI). The kit may further include other materials desirable from a commercial end user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

[0286] In one embodiment, the kit comprises the pharmaceutical composition provided herein, a label identifying the pharmaceutical composition, and an instruction for storage, reconstitution and / or administration of the pharmaceutical compositions to a subject.

[0287] In another embodiment, the kit comprises: (a) an amount of the biologically active construct of the invention sufficient to treat a disease, condition or disorder upon administration to a subject in need thereof; and (b) an amount of a pharmaceutically acceptable carrier; together in a formulation ready for injection or for reconstitution with sterile water, buffer, or dextrose; optionally with a label identifying the biologically active construct and storage and handling conditions, and optionally a sheet of the approved indications for the drug, instructions for the reconstitution and / or administration of the biologically active construct for the use for the prevention and / or treatment of an approved indication, appropriate dosage and safety information, and information identifying the lot and expiration of the drug. In another embodiment of the foregoing, the kit can comprise a second container that can carry a suitable diluent for the composition, the use of which will provide the user with the appropriate concentration of biologically active construct to be delivered to the subject.

[0288] In another embodiment of the foregoing, the kit can comprise hyaluronidase, formulated together with the construct of the invention in the same container, or, alternatively, the hyaluronidase is formulated in a separate container.In another embodiment of the foregoing, the kit includes instructions for the preparation of the subcutaneous composition of the invention, and, optionally, means for the subcutaneous administration.

[0289] Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples are provided by way of illustration, and they are not intended to be limiting of the present invention. Furthermore, the present invention covers all possible combinations of particular and preferred embodiments described herein.

[0290] EXAMPLES

[0291] The present invention is further elucidated through the following illustrative examples, which provide a comprehensive understanding of the invention and its numerous advantages.

[0292] The following examples illustrate the invention.

[0293] Example 1: Synthesis of AAT-based constructs of the invention

[0294] Example 1.1: Production and purification of portion P2 suitable for obtaining linear constructs of formula (I) - Scheme I

[0295] The following DNA corresponding to encoded polypeptide sequences were designed:Table C

[0296] Reference DNA sequence Polypeptide sequence P2_200 SEQ ID NO: 27 SEQ ID NO: 23

[0297] P2_400 SEQ ID NO: 28 SEQ ID NO: 24

[0298]

[0299] P2_600 SEQ ID NO: 29 SEQ ID NO: 25

[0300] using a published procedure (WO2017 / 109087) and applied by Ajinomoto (ChOb, Japan) in combination with the Corynex® expression system as described in Friedrich et al., 2022; doi: 10.1186 / S12934-022-01948-5.

[0301] Starting from the cell-free Corynex culture supernatant or a cell extract of E. coli, the PAS polypeptide was isolated by ammonium sulfate precipitation at 20 °C, using 25 % saturation. After centrifugation, the supernatant was removed and the sediment was resuspended in CEX running buffer (25 mM acetic acid / NaOH, pH 4.5). After dialysis against CEX running buffer (4 °C, overnight) and sterile-filtration (0.2 pm PVDF syringe filter), the P2 solution was subjected to subtractive cation exchange chromatography (CEX) on a Fractogel EMD SOs" column (Merck, Darmstadt, Germany).

[0302] The flow-through was dialyzed against 5 I AEX running buffer (25 mM ammonia / acetic acid pH 9.5) and subjected to subtractive anion exchange chromatography (AEX) on a Fractogel EMD TMAE column (Merck). As confirmed by reverse-phase chromatography (RPC), this procedure resulted in a highly pure P2 polypeptide suitable as starting material for the subsequent activation and AAT-coupling procedure.

[0303] Finally, the purified P2 polypeptide was thoroughly dialyzed against ultra-pure water and lyophilized.

[0304] In a following step (activation step) the purified P2 polypeptide was functionalized at the N-terminus with a bromoacetyl group (for the subsequent coupling step with AAT, see scheme I for more details below). The activation was carried out with a 15-fold molar excess of bromoacetic acid-NHS ester (BrAc-NHS; Apollo Scientific, Manchester, UK) in 100 mM bicarbonate buffer (pH 8.0) for 1 h at 25 °C. Subsequently, remaining BrAc-NHS and free N-hydroxysuccinimide were removed by dialysis against ultra-pure water. ESI-MS showed nearly complete activation of the P2 polypeptide. For storage, the activated P2 polypeptide was lyophilized and kept at -20°C. Example 1.2: Production and purification of portion P2 suitable for obtaining branched constructs of formula (I)

[0305] To generate a branched construct of the invention, a low repetitive DNA sequence coding for a P2 polypeptide consisting of a central Pro-Lys-Pro element flanked by two stretches of 201 Pro / Ala / Ser amino acids each and a Gin residue at the N-terminus was designed using apublished procedure (WO2017 / 10908) and applied by Ajinomoto (DNA: SEQ ID NO: 30; protein: SEQ ID NO: 26) in combination with the Corynex® expression system as in Example 1.1.

[0306] The Q-P2(200K200) polypeptide was purified from the Corynex culture supernatant (volume: 200 ml) as described in Example 1, including an ammonium sulfate precipitation step with 25 % (NH4)2SO4 saturation at 20 °C. As in Example 1.1, it was confirmed by reverse-phase chromatography (RPC) that a highly pure P2 polypeptide was obtained.

[0307] To prepare a derivative of this P2 polypeptide with a central single primary amino group for attachment to the AAT protein using the BrAc-NHS linker, the terminal amino group was protected. Cyclization of the N-terminal Gin residue by incubation in 1 % acetic acid for 72 h at 50 °C resulted in the formation of an N-terminal pyroglutamate residue, which is not nucleophilic under physiological buffer conditions.

[0308] In the next step, the N-terminally protected P2 polypeptide was activated at its central Lys side chain with BrAc-NHS as described in Example 1. For storage, the activated PAS polypeptide was lyophilized and kept at -20°C.

[0309] Example 1.3: Chemical conjugation of AAT with activated P2 polypeptides and purification of the AAT-P2 conjugates

[0310] Human AAT (SEQ ID NO: 2) exhibits a single cysteine residue (located at position 232 in SEQ ID NO: 2), which was employed as attachment site for the bromoacetyl-activated PAS polypeptides. Initially, disulfide-bonded cysteine present in the plasma-derived purified AAT protein (Prolastin-C® (Grifols Therapeutics Inc.)) was detached from its residue Cys232 by incubation with dithiothreitol (DTT) at a concentration of 10 mM for 1 h at room temperature. Then, the AAT solution was subjected to gel filtration using a 5 ml HiTrap column (Cytiva, Freiburg, Germany), eguilibrated in 10 mM Na-citrate pH 6, 100 mM NaCI, and subseguently dialysed against 25 mM Na-borate pH 9 at 4 °C.

[0311] Coupling was achieved by dissolving an eguimolar amount of lyophilized bromoacetyl-PAS from Example 1.1 or 1.2 directly in the AAT solution. The activated PAS was allowed to react with the reduced AAT for 16 h at 25 °C.

[0312] To purify the P2-AAT conjugate from side products and any remaining unconjugated reagents, the reaction mixture was subjected to AEX on a CaptoQ ImpRes column (Cytiva) using 25 mM Na-borate pH 8.0 as running buffer. The P2-AAT conjugate was eluted from the column with a gradient of 0-0.5 M NaCI in 25 mM Na-borate pH 8.0.

[0313] The coupling yield of single-conjugated P2-AAT was in the range of 70-90 % for the different P2 versions used.

[0314] The deconvoluted ESI-MS spectrum, measured on a maXis guadrupole time-of-flight (Q-TOF) mass spectrometer eguipped with an electrospray ionization (ESI) source (Bruker Daltonics,Bremen, Germany) in the positive ion mode, of the non-conjugated AAT (top) shows a mass heterogeneity caused by the glycosylation pattern of AAT. Fig. 7 depicts the mass spectra of the constructs obtained.

[0315] Scheme I

[0316] wherein n represents 200, 400 or 600

[0317] Bromoacetic acid-NHS ester Activation

[0318]

[0319] P2-BrAc -COOH

[0320] Coupling

[0321]

[0322] P2-AAT AAT

[0323] The freeze-dried P2 polypeptide is dissolved in bicarbonate buffer and activated at its N-terminus via reaction with bromoacetic acid-NHS ester. The resulting bromoacetyl derivative of the P2 polypeptide is subsequently mixed with an approximately equimolar amount of AAT in borate buffer, where the site-specific conjugation between the bromoacetamide function of the activated P2 polypeptide and the thiol group of the single free cysteine residue of AAT takes place, resulting in a thioether bond between the two molecules.Scheme II

[0324] NH2Glutamine

[0325] NH2

[0326] (Pro / Ala / Ser^COOH

[0327] Coupling

[0328] AAT-P2_2x200

[0329]

[0330] To obtain a branched P2 polypeptide with a central single amino group, the N-terminal amino group of Q-P2(200K200) is protected by cyclization of glutamine to pyroglutamic acid. The resulting Pga-P2(200K200) polypeptide is dissolvedin bicarbonate buffer and activated at the central Lys side chain with bromoacetic acid-NHS ester. The resulting bromoacetyl derivative is subsequently mixed with an approximately equimolar amount of AAT in borate buffer and a site-specific conjugation between the bromoacetamide function of the activated P2 polypeptide and the thiol group of the single free cysteine residue of AAT takes place, resulting in a thioether bond between the two molecules.

[0331] Example 2: Biological activity at physiological conditions in human whole blood

[0332] In this assay the aim was to confirm the effect of conjugating the amino acidic portion P2 on AAT’s activity.

[0333] To that end, each one of AAT_P2_200, AAT_P2_400, AAT_P2_600 or AAT_P2_(2x200) products was incubated at 37°C with 277 l of human whole blood (hWB) with continuous rotation (Orbit agitator from JP Selecta). The final concentration of AAT was, in each case, 22 pM. PBS was used as a control under the same incubation conditions.

[0334] The biological activity was determined before and after incubation (0, day 1 and day 3). Each time point was performed by triplicate in 1.5 mL tubes. At the end of each time point, whole blood samples were processed to obtain plasma. Briefly, the three replicates of each time point were centrifuged for 10 min at 10.000 rpm and 4°C. The supernatant (plasma) of the centrifuged samples was collected into new 1.5 ml tubes and stored at -80°C until further analysis. A sample of whole blood without the test compound was also processed at time 0 h to obtain “blank” plasma. To determine the anti-elastase activity from human whole blood samples, the following procedure was followed. A Standard Curve was performed starting with a 0.2 mg of AAT / mL Tris-albumin buffer (pH= 8.4) and then six dilutions were made (1 / 24.5, 1 / 28.5, 1 / 36, 1 / 50, 1 / 80, and 1 / 93.5). For the assay control, the necessary predilution of the control generated with rat plasma spiked with a known concentration of AAT_P2_200, AAT_P2_400, AAT_P2_600 or AAT_P2_(2x200) was performed to obtain an approximate activity of 0.2 mg / mL of elastase inhibitory activity. From this, three dilutions (1 / 28.5, 1 / 36, and 1 / 50) were made in Tris-Albumin buffer to ensure they were within the range of the curve. 100 pL of samples diluted in Tris-Albumin buffer were incubated with 50 pL of porcine pancreas elastase at 0.625 U / rnL (Calbiochem) for 10 minutes at 25 °C. Then, 50 pL of N-succinyl-Ala-Ala-Ala-p-nitroanilide (2.25 mg / mL, Sigma) was added for 3 minutes and plate was shaken with gentle agitation. The reaction was stopped by adding 50 pL of 50% acetic acid. After gently agitation and two minutes, the absorbance was read at 405 nm. The correlation between the change in absorbance and the concentration of AAT was linear. The amount of p-nitroanilide released was inversely proportional to the concentration of AAT. Activity of AAT_P2_200, AAT_P2_400, AAT_P2_600 or AAT_P2_ (2x200) was quantified by comparison with the standard curve (following the same protocol based on N-succinyl-Ala-Ala-Ala-p-nitroanilide as described above). The relative error (%) {activity / activity (t=0) x 100) from baseline activity was also calculated (Table 1).

[0335] Under physiological conditions in human whole blood, all AAT with P2 conjugation exhibited biological activity and sustained behavior over the studied time period. This indicates that P2conjugation does not disrupt the biological activity of AAT. (See Fig. 2 together with RE % provided in Table 1).

[0336] Example 3. In vitro stability at physiological conditions in human whole blood

[0337] In this assay the aim was to confirm the effect of conjugating the amino acidic portion P2 on AAT’s stability.

[0338] Each one AAT_P2_200, AAT_P2_400, AAT_P2_600 or AAT_P2_(2x200) was incubated at 37°C with 277 pl of human whole blood (hWB) under continuous rotation (Orbit agitator from JP Selecta). The final concentration of AAT was, in each case, 22 pM.

[0339] The stability was determined before and after incubation (0 and day 7). Each time point was performed by triplicate in 1.5 mL tubes. At the end of each time point incubation, whole blood samples were processed to obtain plasma. Briefly, the three replicates of each time point were centrifuged for 10 min at 10.000 rpm and 4°C. The supernatant (plasma) of centrifuged samples was collected into new 1.5 ml tubes and stored at -80°C until further analysis. A sample of whole blood without the test compound was also processed at time 0 h to obtain “blank” plasma.

[0340] The stability of AAT_P2_200, AAT_P2_400, AAT_P2_600, or AAT_P2_(2x200) in human whole blood was analyzed by comparing samples taken at 0 and at day 7 using Western blot. These samples were prepared as follows: 6.5 pL of diluted sample, 2.5 pL of NuPAGE LDS (4X), and 1 pL of NuPAGE reducing agent (10X).

[0341] After heating 10 minutes at 70°C, 8 pl of these samples and 7 pl of protein standard (SeeBlue Plus2 Pre-Stained, ThermoFisher) were subjected to a 4-12% Bis-Tris SDS-PAGE (ThermoFisher). Following electro-transfer onto a PDVF membrane (Millipore) using an iBIot Western Blot Transfer device, the membrane was washed 3 times in TBS. Then, the membrane was incubated for 1 hour in TBS containing 5% skim milk and washed again 3 times in TBS / 0.05% Tween-20. After this, the membrane was incubated for 1 hour 30 minutes in TBS / 0.05% Tween-20 + 5% skim milk containing 0.0004 mg / mL of AviPA(S) Mab 1.1 Murine Mab (XL-protein). The membrane was then washed 3 times for 3-5 minutes in TBS / 0.05 % Tween-20 and incubated 1 hour with a solution of anti-mouse IgG-HRP (0.0002 mg / mL) conjugate prepared in TBS / 0.05 %+ Tween-20 5% skim milk. After washing the membrane 3 times in TBS / 0.05 % Tween-20, ECL Plus Western Blotting substrate from Pierce was prepared by mixing equal parts of Detection Reagent 1 and Detection Reagent 2 (Thermo Fischer Scientific). To detect the proteins, 5 mL of this substrate was applied to the membranes for 1 minute, using the Fusion Pulse 6 (Vilber).

[0342] The results demonstrated homogeneous signals of AAT_ P2_200, AAT_P2_400, AAT_P2_600 or AAT_P2_(2x200) at all analyzed time points (Fig. 3). No degradation products or signs of aggregation were observed, as no molecular weight modifications were detected. These findingssuggest that all AAT with P2 modifications remain stable in whole blood for at least 7 days and, therefore, are safe products.

[0343] Example 4. In vivo pharmacokinetics of the biologically active constructs of the invention following intravenous (iv) administration

[0344] Hereinafter the human plasma-derived Alpha-1 Antitrypsin employed for comparative purpose was Prolastin-C® Liquid (Grifols Therapeutics Inc.).

[0345] The study was conducted on male and female Wistar rats, each weighing approximately 250 g. The animals were processed in batches of up to two groups per day. On the first day of each batch, the animals were randomized and weighed, thereby establishing the experimental groups (Table 2).

[0346] Table 2. Experimental groups

[0347] Group Product Animal Id Adm. Route Sampling points 10 20 30 40 50 Basal, 5 mm, 1 h, 3h, 6h, 24h, 1 AAT_P2_(2x200) IV 48h, 72h, 96h, 168h, 192h and60240h

[0348] 10 20 30 40 50 Basal, 5 mm, 1 h, 3h, 6h, 24h, 2 AAT P2 600 uoj, ^IOJ, aivj, 48h, 72h, 96h, 168h, 192h and60240h

[0349] 10 20 30 40 50 Basal, 5 mm, 1 h, 3h, 6h, 24h, 3 hAATLJ'LJ' t!,' IV 48h, 72h, 96h, 168h, 192h and

[0350]

[0351] 60240h hAAT= not conjugated (comparative purpose); AAT_P2 are constructs of the invention After the experimental groups were generated, a baseline blood sample of 0.3 mL was drawn from the caudal vein. Subsequently, the test products were prepared and allowed to acclimate to room temperature for 5 minutes before administration.

[0352] The final administration volume of each product was calculated based on the weight of the animals, and the intravenous administration was performed using a 26G needle, following the agreed dosing schedule (Table 3).

[0353] Table 3. Doses and Administration Volumes

[0354] Concentration „ Adm. Volume Product , ,HDose (mg / Kg) , , ... .

[0355] (mg / ml) (mL / Kg) AAT_P2_2x200 29.0 50.0 1.7 AAT_P2_600 25.0 50.0 2.0

[0356]

[0357] hAAT 53.5 50.0 0.9

[0358] hAAT= not conjugated (comparative purpose); AAT_P2 are constructs of the invention Once the administration of the products was completed, 0.3 mL blood samples were taken from the caudal vein at the scheduled times (5 min, 1h, 3h, 6h, 24h, 48h, 72h, 96, 168h and 240h). The blood samples were collected in properly labelled K2-EDTA anticoagulant tubes. Aftercollection, the tubes were centrifuged (2500 x g for 10 minutes at 4°C). The obtained plasma was frozen at -80°C.

[0359] For quantitatively detecting hAAT, AAT_P2_600 and AAT_P2_ (2x200), ELISAs assays were performed. For this, 96 well plates (Maxisorb, NUNC), were coated with 100 pL of a 2 pg / mL solution of the Goat anti-Human AAT (Affinity Biologicals) for hAAT detection, and 50 pL of a 10 pg / mL solution of the anti-mouse AviPA(S) Mab 1.1 Murine Mab (XL-protein) for AAT_P2_600 and AAT_P2_(2x200) detection in Phosphate Buffer (137 mM NaCI, 8.1 mM Na2HPO4, 1.47 mM KH2PO4, 2.7 mM KCI). The plates were incubated for a minimum of 8 hours between 2°C and 8°C or for 1 hour at 37°C with gentle agitation. After removing the coating buffer, the plates were blocked with 200 pl of Phosphate Buffer (137 mM NaCI, 8.1 mM Na2HPO4, 1.47 mM KH2PO4, 2.7 mM KCI) with 0.25% (w / v) Bovine Serum Albumin for 1 hour at 37°C or 8 hours between 2°C and 8°C with gentle agitation. Once the incubation was complete, the plates were equilibrated for 10 minutes at room temperature and washed by dispensing 300 pL of washing solution (137 mM NaCI, 8.1 mM Na2HPO4, 1.47 mM KH2PO4, 2.7 mM KCI) with 0.05% (v / v) Tween 20 into each well. Then, 100 pL of standards, controls and samples diluted in dilution buffer (137 mM NaCI, 8.1 mM Na2HPO4, 1.47 mM KH2PO4, 2.7 mM KCI) with 0.25% (w / v) Bovine Serum Albumin and 0.05% (v / v) Tween 20 were added and incubated for 1 hour at 37°C with gentle agitation.

[0360] For the quantification of hAAT, a purified human plasma derived AAT (Grifols) was used. The standard was initially diluted to achieve a concentration of 50 ng / mL. Subsequently, serial 1 / 2 dilutions were performed until a concentration of 0.78 ng / mL was reached. As a control, a secondary standard of plasma was used as a control and diluted to a concentration that is within the standard curve range.

[0361] For AAT_P2_600 and AAT_P2_(2x200) quantification, the standard used was AAT_P2_600 or AAT_P2_(2x200) products diluted to achieve a concentration of 50 ng / mL. Subsequently, serial 1 / 2 dilutions were performed until a concentration of 0.78 ng / mL was reached. And the control was generated from rat plasma supplemented with a known concentration (1.2 mg / mL) of AAT_P2_600 or AAT_P2_ (2x200). Once the incubation was complete, the plate was washed by dispensing 300 pL of washing solution into each well. Then, 100 pL of detection antibody (Sheep anti-Human AAT HRP conjugated, Affinity Biologicals) diluted to a concentration of 0.02 pg / mL in dilution buffer were added into each well and incubated for 1 hour at room temperature with gentle agitation. Once the incubation was complete, the plate was washed and 100 pL of TMB substrate was added into each well. The plate was incubated for 10 minutes, protected from light. The reaction was stopped by adding 100 pL of stop solution (1M Phosphoric Acid) to each well. The absorbance was read on a microplate reader (BioTek Synergy H1, Agilent) at a wavelength of 450 nm.

[0362] Concentration of hAAT, AAT_P2_600 and AAT_P2_(2x200) in rat plasma was quantified by comparison with standard curves. To estimate the plasma half-life of hAAT, AAT_P2_600, andAAT_P2_ (2x200), the concentration values for each time point were determined and plotted against the time post-intravenous administration.

[0363] Fig. 4 presents the results for hAAT, AAT_P2_600, and AAT_P2_(2x200) at equivalent time points. As it is shown, hAAT plasmatic concentration is close to zero just after 24 hours, being not detectable at 72 hours. Notably, the constructs of the invention remained, after 24 hours, at a significant plasmatic concentration (about 6-fold higher than hAAT) and remained detectable for up to 240 hours (i.e. , more than 3-fold prolonged in time).

[0364] These data were analyzed by fitting non-compartmental analysis with Certara Phoenix WinNonlin ver.8.4. confirming that the constructs of the invention showed a four-fold increase in the half-life with respect to hAAT.

[0365] Example 5. In vivo pharmacokinetics of the biologically active constructs of the invention following subcutaneous (sc) administration

[0366] In this example the pharmacokinetics of hAAT, AAT_P2_600 and AAT_P2_ (2x200) (the same as in Example 4) following subcutaneous administration was analysed.

[0367] The study was conducted on 7-week-old male and female C57BL / 6JOIaHsd mice, obtained from Envigo. The animals were housed in groups of 4 mice per cage at the Animal Facility of the Scientific Park of Barcelona (PCB) and were regularly monitored by the technical staff. They were kept under SPF (Specific Pathogen Free) conditions with free access to standard maintenance food (SAFE A-40; SAFE® DIETS) and autoclaved water. The environmental conditions were maintained at a temperature of 22°C (+ / -2°C), with a relative humidity of 50% (+ / -20%), and a 12:12 light-dark cycle.

[0368] The animals underwent an acclimatization quarantine period of 5 days before starting the dosing and blood collection experiment. Veterinary care was available throughout the study.

[0369] For subcutaneous administration, the study products were administered into the previously shaved right dorsal flank using a syringe fitted with a 26G needle (Table D below).

[0370] Table D

[0371] Concentration „ Adm. Volume Product , ,HDose (mg / Kg) , , ... .

[0372] (mg / ml) (mL / Kg) AAT_P2_2x200 33.8 60.0 1.78 AAT_P2_600 28.0 60.0 2.14

[0373]

[0374] hAAT 30 60.0 2.00Once the compositions were administered, blood samples were collected at the scheduled time points (Baseline, 5 min, 1 h, 3 h, 6 h, 12 h, 24 h, 36 h, 48 h, 60 h, 72 h, 96 h, 168 h, 192 h, 240 h and 336 h). The first three samples from each animal were collected via the submandibular vein, obtaining 0.2 mL of blood. The final sample was obtained via exsanguination through the vena cava, maximizing blood volume collection and euthanizing the animal. Deep anesthesia was induced using vaporized isoflurane (4% for induction, 2% for maintenance) for this procedure. Blood samples were collected in appropriately labeled K2EDTA tubes. Once collected, the tubes were centrifuged (2500G for 10 minutes). The plasma obtained was frozen at -80°C until analysis. The concentration of hAAT, AAT_P2_600 and AAT_P2_(2x200) as well as the half-life were determined as in Example 4.

[0375] Additionally, the percentage of relative bioavailability was determined by comparing the area under the plasma concentration-time curve (AUG) of the subcutaneous formulation with that of the same formulation administered intravenously, according to the following equation: F(%)= (AUCsc / AUCiv)x100.

[0376] The results are summarized in Table E below:

[0377] Table E

[0378] Composition Half-Life (h) Bioavailability hAAT 22.9 ± 1.6 38.5%

[0379] AAT_P2_600 57.7 ± 2.1 58.6%

[0380]

[0381] AAT_P2_(2x200) 38.6 ± 2.4 86.2%

[0382] The constructs of the invention show higher half-life and, unexpectedly, remarkably improved bioavailability when they were subcutaneously administered in relation to native AAT. In other words, incorporating portion P2 into hAAT not only avoids any reduction in the bioavailability of native AAT, but unexpectedly results in a marked improvement.

[0383] This finding is surprising because the incorporation of P2 substantially increases the molecular size of hAAT and the administration route is subcutaneous, which is generally associated with limitations in absorption and systemic exposure for large molecules. Contrary to what would be anticipated from these constraints, the construct of the invention demonstrates enhanced availability, underscoring the inventive nature of the composition.

[0384] Example 6. In vivo biological activity.

[0385] In order to confirm whether the construct of the invention was also functional at such prolonged period of times, plasma samples from the pharmacokinetic study in rats (Example 4 above) were assayed for anti-elastase activity.To that end, a standard curve was generated starting with a 0.2 mg of AAT / mL Tris-albumin buffer (pH= 8.4, 2.5% albumin), and then six dilutions were made (1 / 24.5, 1 / 28.5, 1 / 36, 1 / 50, 1 / 80, and 1 / 93.5). For the assay control, the necessary predilution of the control generated with rat plasma spiked with a known concentration of hAAT, AAT_P2_600 or AAT_P2_(2x200) was performed to obtain an approximate activity of 0.2 mg / mL of elastase inhibitory activity. From this, three dilutions (1 / 28.5, 1 / 36, and 1 / 50) were made with Tris - 2.5% Albumin buffer to ensure they were within the range of the curve. 100 pL of samples diluted in Tris - 2.5% Albumin buffer were incubated with 50 pL of porcine pancreatic elastase at 0.625 U / rnL (Calbiochem) for 10 minutes at 25 °C. Then, 50 pL of N-succinyl-Ala-Ala-Ala-p-nitroanilide (2.25 mg / mL, Sigma) was added for 3 minutes and plate was shaken with gentle agitation. The reaction was stopped by adding 50 pL of 50% acetic acid. After gentle agitation and a 2 minute-incubation, the absorbance was read at 405 nm. The correlation between the change in absorbance and the concentration of AAT was linear. The amount of p-nitroanilide released is inversely proportional to the concentration of AAT. Anti-elastase activity of plasma samples administered with hAAT, AAT_P2_600, or AAT_P2_(2x200) were quantified by comparison with the standard curve.

[0386] Fig. 5 shows the total anti-elastase activity for hAAT, AAT_P2_600, and AAT_P2_(2x200) administered to rats represented as the relative change fold from baseline. An increase in total anti-elastase activity is observed in the animals immediately after administration for all products, with longer duration noted for AAT_P2_600 and AAT_P2_ (2x200). These results reinforce the half-life findings and indicate that the biological activity of the AAT conjugates of the invention are also maintained over the 10-day period.

[0387] Example 7. In vivo Product stability test

[0388] The aim was to confirm whether the constructs of the invention aggregated or degraded with time after being administered to subjects.

[0389] Samples taken at Baseline (5 min) and 10 day during the pharmacokinetic study (Example 4) were subjected to the protocol followed in Example 3. Briefly, 6.5 pL of diluted sample, 2.5 pL of NuPAGE LDS (4X) and 1 pL of NuPAGE reducing agent (10X) were mixed. After heating for 10 minutes at 80°C, 8 pl of these samples and 7 pl of protein marker (SeeBlue Plus2 Pre-Stained, ThermoFisher) were subjected to a 4-12% Bis-Tris SDS-PAGE (ThermoFisher). Following electro-transfer onto a PDVF membrane (Millipore) using an iBIot Western Blot Transfer device, the membrane was washed 3 times in TBS. Then membrane was then incubated for 1 hour in TBS containing 5% skim milk and washed again 3 times in TBS / 0.05 %Tween-20. After this, the membrane was incubated for 1 hour 30 min in TBS / 0.05 %Tween-20 / 5% skim milk containing 0.0004 mg / mL of the AviPA(S) Mab 1.1 Murine Mab (XL-protein). Then, the membrane was washed 3 times for 3-5 minutes in TBS / 0.05 %Tween-20 and incubated 1 hour with a solution of anti-mouse IgG-HRP at 0.0002 mg / mL conjugate (Bio-Rad) prepared in TBS / 0.05 %Tween-20 + 5% skim milk. After washing the membrane 3 times in TBS / 0.05 %Tween-20, ECL Plus WesternBlotting substrate from Pierce was prepared by mixing equal parts of Detection Reagent 1 and Detection Reagent 2 (Thermo Fischer Scientific). 5mL of this substrate was added to the membranes for 1 minute, to detect the proteins using Fusion Pulse 6 (Vilber).

[0390] The blot analysis results (Fig. 6A and 6B) demonstrate no degradation products or signs of aggregation observed as no molecular weight modifications were detected at day 10 with respect to baseline. These findings suggest that all the constructs of the invention remain stable along 10 days in rats. These data confirmed what the inventors concluded in in vitro tests (Fig. 3).

[0391] Example 8. Preliminary lung distribution study.

[0392] Since one of the main therapeutic applications of AAT is focused on lung manifestations of AATD due to insufficient inhibition of neutrophil elastase, including COPD and emphysema, the present inventors analysed the distribution of the constructs of the invention in lungs.

[0393] To that end, bronchoalveolar lavage fluid (BALF) was collected from the study conducted on Wistar rats in Example 4. After the final sampling point obtained, BALF was collected. For this, deep anesthesia was induced using vaporized isoflurane (4% induction, 2% maintenance). Once the animal was asleep, it was euthanized by exsanguination, obtaining the maximum possible volume of blood in EDTA tubes, and centrifuging at 2500 x g for 10 minutes at 4°C to obtain plasma. With the animal euthanized, an incision was made in the ventral neck area, separating the salivary glands and the sternohyoid muscle to expose the trachea. A small incision was then made in the trachea, a 25G catheter was inserted through the incision in the trachea and saline (30 ml / kg) was perfused and aspirated slowly twice. The fluid obtained from the bronchoalveolar lavage was centrifuged for 7 minutes at 4004°C. The supernatant was stored at -80°C.

[0394] BALF from the 6 animals in each group were concentrated using an Amicon 30 KDa filter. To do this, each tube was centrifuged twice at 4000 x g for 5 minutes. After centrifugation, the retained volume was recovered and adjusted with PBS to 50-100 pL. Subsequently, the detection of the constructs of the invention (AAT_P2_600 or AAT_P2_(2x200)) in BALF was carried out by Western blot as disclosed in previous Example 3. To do so, BALF concentrated samples were prepared by mixing as follows: 6.5 pL of sample, 2.5 pL of NuPAGE LDS (4X) and 1 pL of NuPAGE reducing agent (10X).

[0395] After heating 10 minutes at80°C, 8 pl of these samples and 7 pl of protein marker (SeeBlue Plus2 Pre-Stained, ThermoFisher) were subjected to a 4-12% Bis-Tris SDS-PAGE (ThermoFisher). Following electro-transfer onto a PDVF membrane (Millipore) using an iBIot Western Blot Transfer device, membrane was washed 3 times in TBS. Then membrane was incubated for 1h in TBS containing 5% skim milk and washed again 3 times in TBS / 0.05% Tween-20. After this, the membrane was incubated for 1 hour 30 min in TBS / 0.05% Tween-20 / 5% skim milk containing 0.0004 mg / mL of AviPA(S) Mab 1.1 Murine MaB (XL-protein). The membrane was then washed 3 times for 3-5 minutes in TBS / 0.05% Tween-20 and incubated 1 hour with a solution of antimouse IgG-HRP at 0.0002 mg / mL (Bio-Rad) conjugate prepared in TBS / 0.05% Tween-20 / 5%skim milk. After washing the membrane 3 times in TBS / 0.05 % Tween-20, ECL Plus Western Blotting substrate from Pierce was prepared by mixing equal parts of Detection Reagent 1 and Detection Reagent 2 (Thermo Fischer Scientific). To detect the proteins, 5 mL of this substrate was applied to the membranes for 1 minute, using the Fusion Pulse 6 (Vilber).

[0396] Fig.s 7A and 7B display BALF samples containing AAT_P2_600 and AAT_P2_ (2x200). As it can be derived from the collected data, both constructs were confirmed to be present in all samples analyzed at 10 days after administration. These results confirm that in spite of being conjugated AAT to a portion P2, the resulting construct is capable of efficiently reaching the pulmonary area.

[0397] Clauses

[0398] For reasons of completeness, various aspects of the invention are set out in the following numbered clauses:

[0399] Clause 1. A biologically active construct of formula (I) or a pharmaceutically salt thereof:

[0400] P1-X-P2 (I)

[0401] wherein

[0402] (a) P1 represents a first amino acid portion comprising an amino acid sequence corresponding to an a 1 -antitrypsin (AAT) molecule;

[0403] (b) P2 represents a second amino acid portion comprising an amino acid sequence:

[0404] - having a length from 100 to 3000 amino acid residues, and

[0405] - comprising amino acid repetitive units, wherein:

[0406] (i) the repetitive units are the same or different, and

[0407] (ii) each one of the repetitive units comprises at least one Ala, at least one Pro residue, and optionally at least one Ser, in any order; and

[0408] (c) X represents a linker, a peptide bond or a non-peptide bond.

[0409] Clause 2. A biologically active construct of formula (I) or a pharmaceutically salt thereof:

[0410] P1-X-P2 (I)

[0411] wherein

[0412] (a) P1 represents a first amino acid portion comprising an amino acid sequence corresponding to an a 1 -antitrypsin (AAT) molecule;

[0413] (b) P2 represents a second amino acid portion comprising an amino acid sequence:

[0414] - having a length from 100 to 3000 amino acid residues, and- comprising amino acid repetitive units, wherein:

[0415] (i) the repetitive units are the same or different, and

[0416] (ii) each one of the repetitive units comprises at least one Ala, at least one Pro residue, and at least one Ser, in any order; and

[0417] (c) X represents a linker, a peptide bond or a non-peptide bond.

[0418] Clause 3. The biologically active construct according to any one of the preceding clauses, wherein AAT glycoprotein is one having one or more of the following technical features:

[0419] - it is naturally occurring or recombinant,

[0420] - it is fully or partially glycosylated,

[0421] - it corresponds to an isolated fully or partially glycosylated AAT glycoform;

[0422] - it corresponds to a mixture of two or more fully glycosylated AAT glycoforms;

[0423] - it corresponds to a mixture of two or more partially glycosylated AAT glycoforms;

[0424] - it corresponds to a mixture of fully and partially glycosylated AAT glycoforms; wherein the glycoforms are selected from MO to M8.

[0425] Clause 4. The biologically active construct according to any of the preceding clauses, wherein portion P1 has an amino acid length higher or lower than the amino acid length of portion P2; particularly, portion P1 has an amino acid length corresponding to at least 60% of portion P2 amino acid length; particularly, portion P1 has an amino acid length within the range defined by the length of portion P2 amino acid ± 40%, particularly within the range defined by the length of portion P2 amino acid ± 30%, particularly within the range defined by the length of portion P2 amino acid ± 20%, particularly within the range defined by the length of portion P2 amino acid ± 10%.

[0426] Clause 5. The biologically active construct according to any one of the preceding clauses, wherein P1 portion comprises a sequence having at least 80% of identity with an aminoacidic sequence selected from SEQ ID NO: 1 to 14 or a functional fragment thereof; particularly P1 portion comprises a sequence having at least a 85%, particularly at least a 90% of identity with SEQ ID NO: 2 ora functional fragment thereof; particularly P1 portion consists of a sequence having at least 85%, at least 90% of identity with SEQ ID NO: 2 or a functional fragment thereof.

[0427] Clause 6. The biologically active construct according to any one of the preceding clauses, wherein X is a non-peptide bond.

[0428] Clause 7. The biologically active construct according to any one of the preceding clauses, wherein portion P2 has an amino acid length from 100 to 1000 amino acid residues, particularly from 200 to 800 amino acid residues, particularly from 350 to 650 amino acid residues.Clause 8. The biologically active construct according to any of the preceding clauses, wherein the repetitive units comprised in P2 represent at least about 50%, at least about 65%, at least about 75 %, at least about 80 %, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the amino acids forming the portion P2.

[0429] Clause 9. The biologically active construct according to any of the preceding clauses, wherein the repetitive units are the same or different and have an amino acid length from 3 to 50 amino acids; particularly at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, or 30.

[0430] Clause 10. The biologically active construct according to any of the preceding clauses, wherein the repetitive units comprised in P2 are the same.

[0431] Clause 11. The biologically active construct according to any of the preceding clauses, wherein the repetitive units consist of one or more Ala, one or more Ser, and one or more Pro residues, in any order.

[0432] Clause 12. The biologically active construct according to any of the preceding clauses, wherein no more than 6 consecutive amino acid residues are identical, particularly no more than 5 identical consecutive amino acid residues, particularly no more than 4 identical consecutive amino acid residues, particularly no more than 3 identical consecutive amino acid residues.

[0433] Clause 13. The biologically active construct according to any one of the preceding clauses, wherein the total content of Ala is equal or higher than the total content of Pro and Ser residues in portion P2.

[0434] Clause 14. The biologically active construct according to any one of the preceding clauses, wherein the total content of Pro is higher than the total content of Ser residues in portion P2.

[0435] Clause 15. The biologically active construct according to any one of the preceding clauses, wherein Pro residues constitute from 4% to 50%, particularly from 10% to 45%, particularly from 15% to 40%, particularly from 20% to 40% of the total number of amino acids forming portion P2.

[0436] Clause 16. The biologically active construct according to any one of the preceding clauses, wherein Ala residues constitute from 4% to 60 %, particularly from 10% to 55%, particularly from 20% to 55% of the total number of amino acids forming portion P2.

[0437] Clause 17. The biologically active construct according to any one of the preceding clauses, wherein Ser residues constitute from 4% to 50%, particularly from 10% to 45%, particularly from 20% to 40% of the total number of amino acids forming portion P2.Clause 18. The biologically active construct according to any one of the preceding clauses, wherein the total amino acid composition of P2 comprises about 30-40 % proline residues, about 45-55 % alanine residues and about 10-20 % serine residues of the amino acids constituting P2, provided that the sum does not exceed the 100%; particularly, the total amino acid composition of P2 comprises about 35 % proline residues, about 50 % alanine residues and about 15 % serine residues, provided that the sum does not exceed the 100%.

[0438] Clause 19. The biologically active construct according to any one of the preceding clauses, wherein the total amino acid composition of P2 comprises from 30-40 % proline residues, about 10-20 % alanine residues and about 45-55 % serine residues, provided that the sum does not exceed the 100%; particularly, the total amino acid composition of P2 comprises about 35 % proline residues, about 15 % alanine residues and about 50 % serine residues, provided that the sum does not exceed the 100%.

[0439] Clause 20. The biologically active construct according to any one of the preceding clauses, wherein portion P2 consists of alanine, serine and proline residues; particularly portion P2 consists of alanine, serine and proline residues and the plurality of repetitive units are the same.

[0440] Clause 21. The biologically active construct according to any one of the preceding clauses, wherein portion P2 comprises up to 10%, particularly up to 8%, particularly up to 6%, particularly up to 5%, particularly up to 4%, particularly up to 3%, particularly up to 2%, particularly up to 1% of amino acids different from alanine, serine and proline.

[0441] Clause 22. The biologically active construct according to any one of the preceding clauses, wherein portion P2 comprises at least two of the amino acid repetitive units separated by one or more amino acids, particularly by 1 , 2, 3, 4 or 5 amino acids.

[0442] Clause 23. The biologically active construct according to clause 22, wherein two of the amino acid repetitive units are separated by one or more amino acids, particularly by 1, 2, 3, 4 or 5 amino acids.

[0443] Clause 24. The biologically active construct according to any one of the clauses 22-23, wherein the at least two amino acid repetitive units are separated by at least one amino acid other than Ser, Pro or Ala; particularly the at least two amino acid repetitive units are separated by 1, 2, 3, 4, or 5 amino acid residues selected from Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Vai; particularly the at least two amino acid repetitive units are separated by 1, 2, 3, 4, or 5 amino acid residues, the same of different, selected from Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Vai; particularly the at least two amino acid repetitive units are separated by 1, 2, 3, 4, or 5 amino acid residues, the same or different, selected from Cys and Lys;particularly the at least two amino acid repetitive units are separated by amino acid residue selected from Cys and Lys.

[0444] Clause 25. The biologically active construct according to clause 24, wherein portion P2 comprises two of the amino acid repetitive units separated by 2, 3, 4 or 5 amino acids, wherein at least one of these amino acids is other than Ser, Pro or Ala.

[0445] Clause 26. The biologically active construct according to any one of the preceding clauses 22- 25, wherein the repetitive units are the same.

[0446] Clause 27. The biologically active construct according to any one of the preceding clauses 21- 26, wherein the repetitive units have an amino acid length from 15 to 25 amino acids, particularly of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids.

[0447] Clause 28. The biologically active construct according to any of the preceding clauses, wherein the amino acid repetitive unit is selected from sequences SEQ ID NO: 15 to 22, and wherein no more than 6 consecutive amino acid residues are identical, particularly no more than 5 identical consecutive amino acid residues, particularly no more than 4 identical consecutive amino acid residues, particularly no more than 3 identical consecutive amino acid residues.

[0448] Clause 29. The biologically active construct according to any one of the preceding clauses, wherein portion P2 comprises a plurality of amino acid repetitive units, wherein all the repeats are the same and correspond to sequence SEQ ID NO: 15.

[0449] Clause 30. The biologically active construct according to any of the preceding clauses, wherein P2 consists of a plurality of amino acid repetitive units, wherein all the repeats are the same and correspond to sequence SEQ ID NO: 15.

[0450] Clause 31. The biologically active construct according to any one of the preceding clauses, wherein portion P2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 23 to 26, 49-50, and any circular permuted versions and (a) multimers(s) of these sequences as a whole or parts of these sequences.

[0451] Clause 32. The biologically active construct according to any one of the preceding clauses, wherein portion P2 is selected from sequences SEQ ID NO: 23 to 26, 49-50.

[0452] Clause 33. The biologically active construct according to any one of the preceding clauses, wherein portion P1 , portion P2 or both includes an affinity tag, such as the His6-tag or the Strep-tag, a signal peptide, a retention peptide, or a targeting peptide like a membrane translocation peptide.

[0453] Clause 34. The biologically active construct according to any one of the preceding clauses, which is selected from the group consisting of:

[0454] (i) SEQ ID NO. 43 conjugated at Cys232 to Alai of SEQ ID NO: 51 , via Ac (AAT_P2_200),(ii) SEQ ID NO. 44 conjugated at Cys232 to Alai of SEQ ID NO. 52, via Ac (AAT_P2_400), (iii) SEQ ID NO. 45 conjugated at Cys232 to Alai of SEQ ID NO. 53, via Ac (AAT_P2_600), (iv) SEQ ID NO. 46 conjugated at Cys232 to Lys206 of SEQ ID NO. 54, via Ac (AAT_P2_(2x200)), (v) SEQ ID NO. 47 conjugated at Cys232 to Lys206 of SEQ ID NO. 55, via Ac (AAT_P2_(2x200)), and

[0455] (vi) SEQ ID NO. 48 conjugated at Cys232 to Lys205 of SEQ ID NO. 56, via Ac (AAT_P2_(2x200)). Clause 35. A nucleic acid molecule encoding the biologically active construct as defined in any one of the preceding clauses 1 to 34.

[0456] Clause 36. A vector comprising the nucleic acid of clause 35.

[0457] Clause 37. A cell comprising the nucleic acid according to clause 35 or the vector according to clause 36.

[0458] Clause 38. A method for the preparation of the biologically active construct according to any one of clauses 1 to 34, which comprises the steps of (a.1 ) culturing the cell according to clause 35 under suitable conditions for the cell growth, and (a.2) isolating said biologically active construct from the culture; or, alternatively, when X is a non-peptide bond or a non-peptide linker, the process comprises conjugating P1 and portion P2.

[0459] Clause 39. A pharmaceutical composition comprising the biologically active construct according to any one of clauses 1 to 34 or the vector as defined in clause 36, together with one or more pharmaceutically acceptable excipients or carriers.

[0460] Clause 40. The pharmaceutical composition according to clause 39, which is an intravenous or subcutaneous pharmaceutical composition.

[0461] Clause 41. A subcutaneous pharmaceutical composition comprising one or more biologically active constructs as defined in any one of clauses 1 to 34, or the nucleic acid molecule as defined in clause 35, or the vector as defined in clause 36 or the cell as defined in clause 37, together with one or more pharmaceutically acceptable excipients or carriers.

[0462] Clause 42. The subcutaneous pharmaceutical composition of clause 41, which comprises one or more biologically active constructs, which are the same or different, and are selected from: (i) SEQ ID NO. 43 conjugated at Cys232 to Alai of SEQ ID NO: 51, via Ac (AAT_P2_200), (ii) SEQ ID NO. 44 conjugated at Cys232 to Alai of SEQ ID NO. 52, via Ac (AAT_P2_400), (iii) SEQ ID NO. 45 conjugated at Cys232 to Alai of SEQ ID NO. 53, via Ac (AAT_P2_600),

[0463] (iv) SEQ ID NO. 46 conjugated at Cys232 to Lys206 of SEQ ID NO. 54, via Ac (AAT_P2_ (2x200)),(v) SEQ ID NO. 47 conjugated at Cys232 to Lys206 of SEQ ID NO. 55, via Ac (AAT_P2_ (2x200)), and

[0464] (vi) SEQ ID NO. 48 conjugated at Cys232 to Lys205 of SEQ ID NO. 56, via Ac (AAT_P2_ (2x200)).

[0465] Clause 43. The subcutaneous pharmaceutical composition of any of clauses 41-42, wherein the biologically active construct is selected from:

[0466] (a) SEQ ID NO. 45 conjugated at Cys232 to Alai of SEQ ID NO. 53, via Ac (AAT_P2_600), (b) SEQ ID NO. 46 conjugated at Cys232 to Lys206 of SEQ ID NO. 54, via Ac (AAT_P2_(2x200)),

[0467] (c) SEQ ID NO. 47 conjugated at Cys232 to Lys206 of SEQ ID NO. 55, via Ac (AAT_P2_ (2x200)), and

[0468] (d) SEQ ID NO. 48 conjugated at Cys232 to Lys205 of SEQ ID NO. 56, via Ac (AAT_P2_ (2x200)).

[0469] Clause 44. The subcutaneous pharmaceutical composition of any of the preceding clauses 41- 43, which is in lyophilized form.

[0470] Clause 45. The subcutaneous pharmaceutical composition of any of the preceding clauses 41- 43, which is in liquid form.

[0471] Clause 46. The pharmaceutical composition according to any of the preceding clauses 39-45, which comprises one or more agents selected from: an anti-inflammatory agent, such as a non-steroidal anti-inflammatory agent (or NSAID); an antagonist of TNFa; an anti-TNFa antibody; an antagonist of an inflammatory cytokine; agonist of a glucagon-like peptide (GLP) receptor or an agonist of an exendin receptor; an agonist of CD3; or a glycosidase (such as hyaluronidase); particularly the composition comprises hyaluronidase.

[0472] Clause 47. A biologically active construct as defined in any of the preceding clauses 1-34 or the vector as defined in clause 36 or the pharmaceutical composition as defined in clauses 39-46 for use as a medicament.

[0473] Clause 48. A biologically active construct as defined in any of the preceding clauses 1-34 or the vector as defined in clause 36 or the pharmaceutical composition as defined in clauses 39-46 for use as an immunomodulating agent.

[0474] Clause 49. A biologically active construct as defined in any of the preceding clauses 1-34 or the vector as defined in clause 36 or the pharmaceutical composition as defined in clauses 39-46 for use in the treatment or prevention of: inflammation, infection or a a1-antitrypsin- defficient disease.Clause 50. A biologically active construct as defined in any of the preceding clauses 1-34 or the vector as defined in clause 36 or the pharmaceutical composition as defined in clauses 39-46 for use in the treatment or prevention of lung disease such as chronic obstructive pulmonary disease (COPD) (such as emphysema), liver disease, vascular disease (e.g., intracranial aneurysms, arterial fibromuscular dysplasia, severe bleeding disorders, and hypertension), panniculitis, eye disease (e.g., anterior uveitis), systemic necrotizing vasculitis, granulomatosis with polyangiitis, diabetes, ischemic reperfusion injury, organ or non-organ transplant rejection, graft versus host disease (GvHD), infection (particularly the infection comprises a bacterial, viral, fungal or parasitic infection), a lung condition or lung infection (such as an inflammatory lung disease comprising chronic pulmonary obstructive disease (COPD) or emphysema or other inflammatory lung disease); particularly for use in the treatment or prevention of one or more of rheumatoid arthritis, lupus, systemic lupus erythematosus (SLE), chronic inflammation of coronary arteries, Crohn's Disease, inflammatory bowel disease (IBD), ulcerative colitis, gastroduodenitis, Celiac disease, Sprue, Celiac sprue dermatitis, chronic pulmonary obstructive disease (COPD), emphysema, systemic inflammatory response syndrome (SIRS), asthma, Sjogren's syndrome, scleroderma, dermatomyositis, polymyositis, Reiter's syndrome, Behcet's disease, multiple sclerosis, myasthenia gravis, or encephalomyelitis, Hashimoto's thyroiditis, Graves' Disease, uveitis, Alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, Bullous pemphigoid, cardiomyopathy, chronic inflammatory demyelinating polyneuropathy, fibromyalgia-fibromyositis, Glomerulonephritis, Guillain- Barre, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA neuropathy, Juvenile arthritis, Lichen planus, Meniere's disease, mixed connective tissue disease, Myasthenia gravis, Pemphigus vulgaris, Pernicious anemia, Polyarteritis nodosa, Polychrondritis, Polyglandular syndromes, Polymyalgia rheumatic, Polymyositis and dermatomyositis, Primary agammaglobulinemia, Primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynauld's phenomenon, Reiter's syndrome, Sarcoidosis, Scleroderma, Stiff-man syndrome, Takayasu arteritis, Temporal arteristis / giant cell arteritis, dermatitis herpetiformis vasculitis, Vitiligo, Wegener's granulomatosis, inflammatory osteolysis, osteoporosis, chronic inflammation (e.g. from chronic viral or bacterial infections), encephalitis, spinal nerve or cord injury, tenosynovitis, psoriasis (e.g., plaque psoriasis, pustular psoriasis, erythrodermic psoriasis, guttate psoriasis or inverse psoriasis), liver cirrhosis, acute-on-chronic liver failure, pulmonary fibrosis, undifferentiated arthropathy, undifferentitated spondyloarthropathy, fibrosarcoma, myxo sarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, Kaposi's sarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, rhabdosarcoma,colorectal carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, melanoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, myeloma, lymphoma, leukemia, sepsis, atherosclerosis, Alzheimer's disease, muscular dystrophy, Down’s syndrome, stroke, neurodegenerative disorders, preventing or treating GVHD, treating a subject undergoing an organ or non-organ (such as prothesis) transplant comprising a heart, lung, intestinal, liver, pancreas, kidney, soft tissue, facial component, pancreatic islet cells, stem cells, bone marrow cells, or corneal epithelial transplants, before, during or after plastic, cosmetic surgery or reconstructive surgery, (e.g. elective, burns; traumatic injuries, mastectomy, breast implants, congenital abnormalities, such as cleft palates or cleft lips; developmental abnormalities), wound healing, osteoarthritis, acute respiratory distress syndrome, bronchiectasis, retinopathies (e.g. diabetic retinopathy), age macular degeneration, drug induced liver injury (including ILICI (immune-mediated liver injury from immune checkpoint inhibitors), CHILI (Checkpoint Inhibitor-induced Liver Injury), pregnancy disorders (e.g. spontaneous premature birth, abortion, gestational hypertension), myocardial ischemia, chronic systemic arterial and venous hypertension, pulmonary arterial and venous hypertension, congenital heart disease (with and without intracardiac shunting), valvular heart disease, idiopathic dilated cardiomyopathy, infectious and non-infectious myocarditis, stress cardiomyopathy, septic cardiomyopathy, atrial and ventricular arrhythmias, endocarditis, pericarditis, ventricular remodeling, concentric hypertrophy, eccentric hypertrophy, renal disorders and failure, or gout.

[0475] Clause 51. The biologically active construct as defined in any of the preceding clauses 1-34 or the vector as defined in clause 36 or the pharmaceutical composition as defined in clauses 39-46 for use according to clauses 47-50 in combination with one or more of an antiinflammatory agent, such as a non-steroidal anti-inflammatory agent (or NSAID); an antagonist of TNFa; an anti-TNFa antibody; an antagonist of an inflammatory cytokine; agonist of a glucagon-like peptide (GLP) receptor or an agonist of an exendin receptor; an agonist of CD3; or a glycosidase (such as hyaluronidase); particularly in combination with a glycosidase, more particularly in combination with hyaluronidase.

[0476] Clause 52. The biologically active construct as defined in any of the preceding clauses 1-34 or the nucleic acid as defined in clause 35 or vector as defined in clause 36 or the cell asdefined in clause 37 or the pharmaceutical composition as defined in any of the clauses 39- 46, for use according to any of the claims 47-51 , wherein the construct, nucleic acid, vector, cell or pharmaceutical composition is administered by subcutaneous or intravenous route. Clause 53. The biologically active construct as defined in any of the preceding clauses 1-34 or the nucleic acid as defined in clause 35 or vector as defined in clause 36 or the cell as defined in clause 37 or the pharmaceutical composition as defined in any of the clauses 39-46, for use according to any of the clauses 47-52, wherein the construct, nucleic acid, vector, cell or pharmaceutical composition is administered by subcutaneous route.

[0477] Clause 54. The biologically active construct as defined in any of the preceding clauses 1-34 or the nucleic acid as defined in clause 35 or vector as defined in clause 36 or the cell as defined in clause 37 or the pharmaceutical composition as defined in any of the clauses 39-46, for use according to any of the clauses 47-53, wherein the construct, nucleic acid, vector, cell or pharmaceutical composition is administered by subcutaneous route in combination with hyaluronidase.

[0478] Clause 55. The biologically active construct as defined in any of the preceding clauses 1-34 or the nucleic acid as defined in clause 35 or vector as defined in clause 36 or the cell as defined in clause 37 or the pharmaceutical composition as defined in any of the clauses 39-46, for use according to any of the clauses 47-54, wherein the construct, nucleic acid, vector, cell or pharmaceutical composition is administered by subcutaneous route in combination with hyaluronidase, the composition and the hyaluronidase being administered consecutively, simultaneously or separately.

[0479] Clause 56. A unit dosage form comprising the pharmaceutical composition as defined in any of the preceding clauses 39-46.

[0480] Clause 57. A kit comprising the biologically active construct as defined in any one of the clauses 1 to 34, the nucleic acid according to clause 35, the vector according to clause 36, the cell according to clause 37, or the pharmaceutical composition as defined in any one of the clauses 39-46, or the unit dosage form according to clause 56, together with auxiliary means and / or instructions for the preparation and / or administration of the composition; or, alternatively, P1 and P2 amino acidic portions in separate compartments together with auxiliary means and instructions for preparing the construct.

[0481] Clause 58. The kit of clause 57, wherein the composition is in liquid form.

[0482] Clause 59. The kit of clause 57, wherein the composition is in lyophilized form.

[0483] Clause 60. The kit of any of the clauses 57-59, which includes instructions for the preparation and / or administration of the subcutaneous composition as defined in any of the clauses 41-45, and, optionally, means for the subcutaneous administration.Clause 61. The pharmaceutical composition according to clause 39-40, the subcutaneous pharmaceutical composition according to any of the clauses 41-46, the unit dosage form according to clause 54, or the kit according to any of the clauses 57-60, further comprising hyaluronidase.

Claims

CLAIMS1. A biologically active construct of formula (I)P1-X-P2 (I)wherein(a) P1 represents a first amino acid portion comprising an amino acid sequence corresponding to an a1 -antitrypsin (AAT) glycoprotein;(b) P2 represents a second amino acid portion comprising an amino acid sequence:- having a length from 100 to 3000 amino acid residues, particularly from 100 to 1000 amino acid residues, particularly from 200 to 800 amino acid residues, particularly from 350 to 650 amino acid residues, and- comprising amino acid repetitive units, wherein:(i) the repetitive units are the same or different, and(ii) each one of the repetitive units comprises at least one Ala, at least one Ser, and at least one Pro residue, in any order; and(c) X represents a linker, a peptide bond or a non-peptide bond.

2. The biologically active construct according to any one of the preceding claims, wherein P1 portion comprises a sequence having at least 80% of identity with an aminoacidic sequence selected from SEQ ID NO: 1 to 14 or a functional fragment thereof; particularly P1 portion comprises a sequence having at least a 85%, particularly at least a 90% of identity with SEQ ID NO: 2 or a functional fragment thereof; particularly P1 portion consists of a sequence having at least 85%, at least 90% of identity with SEQ ID NO: 2 or a functional fragment thereof.

3. The biologically active construct according to any one of the preceding claims, wherein AAT glycoprotein is one having one or more of the following technical features:- it is naturally occurring or recombinant,- it is fully or partially glycosylated,- it corresponds to an isolated fully or partially glycosylated AAT glycoform;- it corresponds to a mixture of two or more fully glycosylated AAT glycoforms;- it corresponds to a mixture of two or more partially glycosylated AAT glycoforms;- it corresponds to a mixture of two or more fully and partially glycosylated AAT glycoforms.

4. The biologically active construct according to any one of the preceding claims, wherein X is a non-peptide bond.

5. The biologically active construct according to any of the preceding claims, wherein the repetitive units:(i) represent at least about 50%, at least about 65%, at least about 75 %, at least about 80 %, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the amino acids forming the portion P2; and / or(ii) are the same or different and have an amino acid length from 3 to 50 amino acids; particularly from 15 to 25 amino acids, particularly of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids.

6. The biologically active construct according to any of the preceding claims, wherein the repetitive units comprised in P2 are the same, and consist of one or more Ala, one or more Ser, and one or more Pro residues, in any order, provided that no more than 6 consecutive amino acid residues are identical, particularly no more than 5 identical consecutive amino acid residues, particularly no more than 4 identical consecutive amino acid residues, particularly no more than 3 identical consecutive amino acid residues.

7. The biologically active construct according to any one of the preceding claims, wherein the portion P2 has an amino acid composition selected from the following options (i) to (v):(i) from 4 to 50% of Pro residues, particularly from 10 to 45%, particularly from 15% to 40%, particularly from 20% to 40%; from 4% to 60 % of Ala residues, particularly from 10% to 55%, particularly from 20% to 55%; and from 4% to 50% of Ser residues, particularly from 10% to 45%, particularly from 20% to 40%, provided that the sum does not exceed the 100%; or,(ii) 30-40 % of Pro residues, 45-55 % of Ala residues, and 10-20 % Ser residues, provided that the sum does not exceed the 100%;(iii) 35 % of Pro residues, 50 % of Ala residues, and 15 % of Ser residues;(iv) 30-40 % of Pro residues, 10-20 % of Ala residues, and 45-55 % of Ser residues, provided that the sum does not exceed the 100%;(v) 35 % of proline residues, 15 % alanine residues, and 50 % of Ser;the % being expressed as the number of Pro, Ala and Ser residues with respect to the total number of amino acids forming portion P2.

8. The biologically active construct according to any one of the preceding claims, wherein portion P2 (i) consists of alanine, serine and proline residues; particularly portion P2 consists of alanine, serine and proline residues and the plurality of repetitive units are the same.

9. The biologically active construct according to any one of the preceding claims 1-8, wherein portion P2 comprises up to 10%, particularly up to 8%, particularly up to 6%, particularly up to 5%, particularly up to 4%, particularly up to 3%, particularly up to 2%, particularly up to 1% of amino acids different from alanine, serine and proline.

10. The biologically active construct according to claims 1-9, wherein portion P2 comprises at least two of the amino acid repetitive units separated by one or more amino acids, particularly by 1 , 2, 3, 4 or 5 amino acids; particularly wherein two of the amino acid repetitive units are separated by one or more amino acids, particularly by 1 , 2, 3, 4 or 5 amino acids other than Ser, Pro or Ala; particularly the at least two amino acid repetitive units are separated by 1, 2, 3, 4, or 5 amino acid residues selected from Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Vai; particularly the at least two amino acid repetitive units are separated by 1, 2, 3, 4, or 5 amino acid residues, the same of different, selected from Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Vai; particularly the at least two amino acid repetitive units are separated by 1, 2, 3, 4, or 5 amino acid residues, the same or different, selected from Cys and Lys; particularly the at least two amino acid repetitive units are separated by an amino acid residue selected from Cys and Lys.

11. The biologically active construct according to any of the preceding claims, wherein the amino acid repetitive unit is selected from sequences SEQ ID NO: 15 to 22, and wherein no more than 6 consecutive amino acid residues are identical, particularly no more than 5 identical consecutive amino acid residues, particularly no more than 4 identical consecutive amino acid residues, particularly no more than 3 identical consecutive amino acid residues.

12. The biologically active construct according to any one of the preceding claims, wherein portion P2 comprises or consists of a plurality of amino acid repetitive units, wherein all the repeats are the same and correspond to sequence SEQ ID NO: 15; particularly, portion P2 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 23 to 26, 49-50, and any circular permuted versions and (a) multimers(s) of these sequences as a whole or parts of these sequences.

13. The biologically active construct according to any one of the preceding claims, which is selected from the group consisting of:(i) SEQ ID NO. 43 conjugated at Cys232 to Alai of SEQ ID NO: 51, via Ac (AAT_P2_200), (ii) SEQ ID NO. 44 conjugated at Cys232 to Alai of SEQ ID NO. 52, via Ac (AAT_P2_400), (iii) SEQ ID NO. 45 conjugated at Cys232 to Alai of SEQ ID NO. 53, via Ac (AAT_P2_600), (iv) SEQ ID NO. 46 conjugated at Cys232 to Lys206 of SEQ ID NO. 54, via Ac (AAT_P2_(2x200)), (v) SEQ ID NO. 47 conjugated at Cys232 to Lys206 of SEQ ID NO. 55, via Ac (AAT_P2_(2x200)), and(vi) SEQ ID NO. 48 conjugated at Cys232 to Lys205 of SEQ ID NO. 56, via Ac (AAT_P2_(2x200)).

14. A nucleic acid molecule encoding the biologically active construct as defined in any one of the preceding claims 1 to 13.

15. A vector comprising the nucleic acid of claim 14.

16. A cell comprising the nucleic acid according to claim 14 or the vector according to claim 15.

17. A pharmaceutical composition comprising the biologically active construct according to any one of claims 1 to 13 or the nucleic acid molecule as defined in claim 14 or the vector as defined in claim 15 or the cell as defined in claim 16, together with one or more pharmaceutically acceptable excipients or carriers; particularly the pharmaceutical composition is an intravenous or subcutaneous pharmaceutical composition.

18. A subcutaneous pharmaceutical composition comprising one or more biologically active constructs as defined in any one of claims 1 to 13 or the nucleic acid molecule as defined in claim 14 or the vector as defined in claim 15 or the cell as defined in claim 16, together with one or more pharmaceutically acceptable excipients or carriers.

19. The subcutaneous pharmaceutical composition according to claim 17 or 18, which comprises one or more biologically active constructs, which are the same or different, and are selected from: (i) SEQ ID NO. 43 conjugated at Cys232 to Alai of SEQ ID NO: 51 , via Ac (AAT_P2_200), (ii) SEQ ID NO. 44 conjugated at Cys232 to Alai of SEQ ID NO. 52, via Ac (AAT_P2_400), (iii) SEQ ID NO. 45 conjugated at Cys232 to Alai of SEQ ID NO. 53, via Ac (AAT_P2_600), (iv) SEQ ID NO. 46 conjugated at Cys232 to Lys206 of SEQ ID NO. 54, via Ac (AAT_P2_(2x200)), (v) SEQ ID NO. 47 conjugated at Cys232 to Lys206 of SEQ ID NO. 55, via Ac (AAT_P2_(2x200)), and(vi) SEQ ID NO. 48 conjugated at Cys232 to Lys205 of SEQ ID NO. 56, via Ac (AAT_P2_(2x200)).

20. The subcutaneous pharmaceutical composition of any of claims 17-19, wherein the biologically active construct is selected from:(a) SEQ ID NO. 45 conjugated at Cys232 to Alai of SEQ ID NO. 53, via Ac (AAT_P2_600), (b) SEQ ID NO. 46 conjugated at Cys232 to Lys206 of SEQ ID NO. 54, via Ac (AAT_P2_(2x200)), (c) SEQ ID NO. 47 conjugated at Cys232 to Lys206 of SEQ ID NO. 55, via Ac (AAT_P2_(2x200)), and(d) SEQ ID NO. 48 conjugated at Cys232 to Lys205 of SEQ ID NO. 56, via Ac (AAT_P2_(2x200)).

21. The pharmaceutical composition of any of the preceding claims 17-20, which is in lyophilized form.

22. The pharmaceutical composition of any of the preceding claims 17-20, which is in liquid form.

23. A biologically active construct as defined in any of the preceding claims 1-13 or the nucleic acid as defined in claim 14 or the vector as defined in claim 15 or the cell as defined in claim 16 or the pharmaceutical composition as defined in any of the preceding claims 17-22 for use as a medicament.

24. A biologically active construct as defined in any of the preceding claims 1-13 or the nucleic acid as defined in claim 14 or the vector as defined in claim 15 or the cell as defined in claim 16 or the pharmaceutical composition as defined in any of the preceding claims 17-22 for use as an immunomodulating agent.

25. A biologically active construct as defined in any of the preceding claims 1-13 or the nucleic acid as defined in claim 14 or the vector as defined in claim 15 or the cell as defined in claim 16 or the pharmaceutical composition as defined in any of the preceding claims 17-22, for use in the treatment or prevention of: inflammation, infection or a a1-antitrypsin-defficient disease; particularly in the treatment or prevention of lung disease such as chronic obstructive pulmonary disease (COPD) (such as emphysema), liver disease, vascular disease (e.g., intracranial aneurysms, arterial fibromuscular dysplasia, severe bleeding disorders, and hypertension), panniculitis, eye disease (e.g., anterior uveitis), systemic necrotizing vasculitis, granulomatosis with polyangiitis, diabetes, ischemic reperfusion injury, organ or non-organ transplant rejection, graft versus host disease (GvHD), infection (particularly the infection comprises a bacterial, viral, fungal or parasitic infection), a lung condition or lung infection (such as an inflammatory lung disease comprising chronic pulmonary obstructive disease (COPD) or emphysema or other inflammatory lung disease); particularly for use in the treatment or prevention of one or more of rheumatoid arthritis, lupus, systemic lupus erythematosus (SLE), chronic inflammation of coronary arteries, Crohn's Disease, inflammatory bowel disease (IBD), ulcerative colitis, gastroduodenitis, Celiac disease, Sprue, Celiac sprue dermatitis, chronic pulmonary obstructive disease (COPD), emphysema, systemic inflammatory response syndrome (SIRS), asthma, Sjogren's syndrome, scleroderma, dermatomyositis, polymyositis, Reiter's syndrome, Behcet's disease, multiple sclerosis, myasthenia gravis, or encephalomyelitis, Hashimoto's thyroiditis, Graves' Disease, uveitis, Alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, Bullous pemphigoid, cardiomyopathy, chronic inflammatory demyelinating polyneuropathy, fibromyalgia-fibromyositis, Glomerulonephritis, Guillain-Barre, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA neuropathy, Juvenile arthritis, Lichen planus, Meniere's disease, mixed connective tissue disease, Myasthenia gravis, Pemphigus vulgaris, Pernicious anemia, Polyarteritis nodosa, Polychrondritis, Polyglandular syndromes, Polymyalgia rheumatic, Polymyositis and dermatomyositis, Primary agammaglobulinemia, Primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynauld's phenomenon, Reiter's syndrome, Sarcoidosis, Scleroderma, Stiff-man syndrome, Takayasu arteritis, Temporal arteristis / giant cell arteritis, dermatitis herpetiformis vasculitis, Vitiligo, Wegener's granulomatosis, inflammatory osteolysis, osteoporosis, chronic inflammation (e.g. from chronic viral or bacterial infections), encephalitis, spinal nerve or cord injury, tenosynovitis, psoriasis (e.g., plaque psoriasis, pustular psoriasis, erythrodermic psoriasis, guttate psoriasis or inverse psoriasis), liver cirrhosis, acute-on-chronicliver failure, pulmonary fibrosis, undifferentiated arthropathy, undifferentitated spondyloarthropathy, fibrosarcoma, myxo sarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, Kaposi's sarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, rhabdosarcoma, colorectal carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, melanoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, myeloma, lymphoma, leukemia, sepsis, atherosclerosis, Alzheimer's disease, muscular dystrophy, Down’s syndrome, stroke, neurodegenerative disorders, preventing or treating GVHD, treating a subject undergoing an organ or non-organ (such as prothesis) transplant comprising a heart, lung, intestinal, liver, pancreas, kidney, soft tissue, facial component, pancreatic islet cells, stem cells, bone marrow cells, or corneal epithelial transplants, before, during or after plastic, cosmetic surgery or reconstructive surgery, (e.g. elective, burns; traumatic injuries, mastectomy, breast implants, congenital abnormalities, such as cleft palates or cleft lips; developmental abnormalities), wound healing, osteoarthritis, acute respiratory distress syndrome, bronchiectasis, retinopathies (e.g. diabetic retinopathy), age macular degeneration, drug induced liver injury (including ILICI (immune-mediated liver injury from immune checkpoint inhibitors), CHILI (Checkpoint Inhibitor-induced Liver Injury), pregnancy disorders (e.g. spontaneous premature birth, abortion, gestational hypertension), myocardial ischemia, chronic systemic arterial and venous hypertension, pulmonary arterial and venous hypertension, congenital heart disease (with and without intracardiac shunting), valvular heart disease, idiopathic dilated cardiomyopathy, infectious and non-infectious myocarditis, stress cardiomyopathy, septic cardiomyopathy, atrial and ventricular arrhythmias, endocarditis, pericarditis, ventricular remodeling, concentric hypertrophy, eccentric hypertrophy, renal disorders and failure, or gout.

26. The biologically active construct as defined in any of the preceding claims 1-13 or the nucleic acid as defined in claim 14 or vector as defined in claim 15 or the cell as defined in claim 16 or the pharmaceutical composition as defined in any of the claims 17-22, for use according to any of the claims 23-25 in combination with one or more of an anti-inflammatory agent, such as a nonsteroidal anti-inflammatory agent (or NSAID); an antagonist of TNFa; an anti-TNFa antibody; an antagonist of an inflammatory cytokine; agonist of a glucagon-like peptide (GLP) receptor or an agonist of an exendin receptor; an agonist of CD3; or a glycosidase (such as hyaluronidase);particularly in combination with a glycosidase, more particularly in combination with hyaluronidase.

27. The biologically active construct as defined in any of the preceding claims 1-13 or the nucleic acid as defined in claim 14 or vector as defined in claim 15 or the cell as defined in claim 16 or the pharmaceutical composition as defined in any of the claims 17-22, for use according to any of the claims 23-26, wherein the construct, nucleic acid, vector, cell or pharmaceutical composition is administered by subcutaneous or intravenous route.

28. The biologically active construct as defined in any of the preceding claims 1-13 or the nucleic acid as defined in claim 14 or vector as defined in claim 15 or the cell as defined in claim 16 or the pharmaceutical composition as defined in any of the claims 17-22, for use according to any of the claims 23-27, wherein the construct, nucleic acid, vector, cell or pharmaceutical composition is administered by subcutaneous route.

29. The biologically active construct as defined in any of the preceding claims 1-13 or the nucleic acid as defined in claim 14 or vector as defined in claim 15 or the cell as defined in claim 16 or the pharmaceutical composition as defined in any of the claims 17-22, for use according to any of the claims 23-28, wherein the construct, nucleic acid, vector, cell or pharmaceutical composition is administered by subcutaneous route in combination with hyaluronidase.

30. A unit dosage form comprising the pharmaceutical composition as defined in any of the preceding claims 17-22.

31. A kit comprising the biologically active construct as defined in any of the preceding claims 1-13 or the nucleic acid as defined in claim 14 or the vector as defined in claim 15 or the cell as defined in claim 16 or the pharmaceutical composition as defined in any of the claims 17-22 or the unit dosage form of claim 30, together with auxiliary means and / or instructions for the preparation and / or administration of the composition; or, alternatively, P1 and P2 amino acidic portions in separate compartments together with auxiliary means and instructions for preparing the construct.

32. The kit of claim 31 , wherein the composition is in liquid form.

33. The kit of claim 32, wherein the composition is in lyophilized form.

34. The kit of any of the claims 31-33, which includes instructions for the preparation of the subcutaneous composition as defined in any of the claims 18-22, and, optionally, means for the subcutaneous administration.

35. The pharmaceutical composition according to claim 17, the subcutaneous pharmaceutical composition according to any of the claims 18-22, the unit dosage form according to claim 30, or the kit according to any of the claims 31-34, further comprising hyaluronidase.